

Deep learning and CRISPR-Cas13d ortholog discovery for optimized RNA targeting

Jingyi Wei^{1,2,3}, Peter Lotfy⁴, Kian Faizi⁴, Sara Baungaard³, Emily Gibson³, Eleanor Wang^{4,5,6}, Hannah Slabodkin^{2,3}, Emily Kinnaman^{2,3}, Sita Chandrasekaran^{3,5,6}, Hugo Kitano⁷, Matthew G. Durrant^{3,5,6}, Connor V. Duffy^{3,8}, Patrick D. Hsu^{3,5,6*}, Silvana Konermann^{2,3*}

¹Department of Bioengineering, Stanford University, Stanford, CA

²Department of Biochemistry, Stanford University, Stanford, CA

³Arc Institute, Palo Alto, CA

⁴Laboratory of Molecular and Cell Biology, Salk Institute for Biological Studies, La Jolla, CA

⁵Department of Bioengineering, University of California, Berkeley, Berkeley, CA

⁶Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA

⁷Department of Computer Science, Stanford University, Stanford, CA

⁸Department of Genetics, Stanford University, Stanford, CA

*Corresponding author

Correspondence: silvanak@stanford.edu (S.K.), pdhsu@berkeley.edu (P.D.H.)

41 Abstract

42

43 Transcriptome engineering technologies that can effectively and precisely perturb mammalian
44 RNAs are needed to accelerate biological discovery and RNA therapeutics. However, the broad
45 utility of programmable CRISPR-Cas13 ribonucleases has been hampered by an incomplete
46 understanding of the design rules governing guide RNA activity as well as cellular toxicity
47 resulting from off-target or collateral RNA cleavage. Here, we sought to characterize and
48 develop Cas13d systems for efficient and specific RNA knockdown with low cellular toxicity in
49 human cells. We first quantified the performance of over 127,000 RfxCas13d (CasRx) guide
50 RNAs in the largest-scale screen to date and systematically evaluated three linear, two
51 ensemble, and two deep learning models to build a guide efficiency prediction algorithm
52 validated across multiple human cell types in orthogonal validation experiments
53 (<https://www.RNAtargeting.org>). Deep learning model interpretation revealed specific sequence
54 motifs at spacer position 15-24 along with favored secondary features for highly efficient guides.
55 We next identified 46 novel Cas13d orthologs through metagenomic mining for activity and
56 cytotoxicity screening, discovering that the metagenome-derived DjCas13d ortholog achieves
57 low cellular toxicity and high transcriptome-wide specificity when deployed against high
58 abundance transcripts or in sensitive cell types, including human embryonic stem cells, neural
59 progenitor cells, and neurons. Finally, our Cas13d guide efficiency model successfully
60 generalized to DjCas13d, highlighting the utility of a comprehensive approach combining
61 machine learning with ortholog discovery to advance RNA targeting in human cells.

62

63

* * *

64

65

66

67 Introduction

68 The ability to perturb desired RNA molecules with high efficiency and specificity is required for
69 functional elucidation of the transcriptome and its diverse phenotypes. Despite rapid progress in
70 effective technologies for genome engineering, analogous systems for transcriptome
71 engineering lag behind their DNA counterparts. While RNAi has long been used for RNA
72 knockdown, it is challenging to engineer and suffers from widespread off-target effects (Jackson
73 et al., 2003; Sigoillot et al., 2012) due to its important role in endogenous miRNA processing
74 (Doench et al., 2003). The discovery and development of RNA-guided RNA-targeting CRISPR
75 systems, such as Cas13 enzymes, provides an orthogonal and modular approach to overcome
76 these limitations (Abudayyeh et al., 2016; East-Seletsky et al., 2016). Because CRISPR
77 proteins are orthogonal to eukaryotic systems, they can be easily engineered to bind or cleave
78 target RNA molecules. Further, their modular nature enables the facile fusion of effector
79 domains to expand effector functionality. As a result, a broad suite of Cas13-based tools is now
80 able to perturb RNA expression (Abudayyeh et al., 2017; Konermann et al., 2018) or splicing
81 (Konermann et al., 2018), mediate RNA editing (Abudayyeh et al., 2019; Cox et al., 2017; Xu et
82 al., 2021) or methylation (Wilson et al., 2020), as well as profile RNA-protein interactions (Han
83 et al., 2020). These capabilities are now accelerating applications across the study of
84 fundamental RNA biology, RNA-based therapeutics, and molecular diagnostics.

85
86 The Cas13 family is unified by the presence of two conserved HEPN ribonuclease motifs, and
87 these enzymes are activated by binding to cognate target RNA as specified by the Cas13 guide
88 RNA (Abudayyeh et al., 2016; East-Seletsky et al., 2016; Slaymaker et al., 2021; Zhang et al.,
89 2018). Several subtypes have been defined on the basis of sequence diversity and domain
90 architecture. Cas13d enzymes – in particular the engineered Cas13d from *R. flavefaciens* strain
91 *XPD3002* (CasRx) (Konermann et al., 2018) – are the smallest and most efficient Cas13 RNA
92 targeting effectors in mammalian and plant cells reported to date (Wessels et al., 2020; Li et al.,
93 2021; Mahas et al., 2019), motivating their further characterization and optimization as RNA
94 targeting tools. In order to successfully apply Cas13d in high-throughput applications, the ability
95 to design highly effective guide RNAs is critical. Recent efforts to understand and predict
96 Cas13d guide activity have taken a first step in this direction, by using a dataset of 2,918 guide
97 RNAs across four transcripts to train a random forest model (Wessels et al., 2020) and by using
98 combined datasets of 10,279 guides to train a deep learning model (Cheng et al. 2023). In
99 addition to the relatively small datasets, the manual selection of guide sequence features
100 (Wessels et al., 2020) or lack of secondary features (Cheng et al. 2023) has limited a broader
101 understanding of Cas13d targeting preferences.

102
103 Here, we conducted the largest Cas13d screen to date, quantifying CasRx guide efficiency
104 across >127,000 guide RNAs tiling 55 essential transcripts by measuring their effects on cell
105 proliferation in human cells. We systematically compared a series of computational models on
106 this dataset to predict guide activity. A deep learning convolutional neural network (CNN) model
107 was able to most accurately predict highly effective guides. Model interpretation enabled us to
108 discover a preferred sequence motif at spacer position 15-24 along with a preference for low
109 guide free energy and high target region accessibility for high efficiency guides. We validated

110 the model against orthogonal datasets and confirmed high accuracy across target transcripts
111 and five different cell types.

112
113 Across the Cas13 subtypes structurally characterized to date, the RNA cleavage site formed by
114 the two HEPN domains is located distal to the guide binding groove (Liu et al., 2017; Slaymaker
115 et al., 2021; Zhang et al., 2018), which can result in the cleavage of non-target bystander RNA
116 molecules (known as ‘collateral’ cleavage) *in vitro* by the HEPN domains activated upon target
117 RNA binding. Initial reports for Cas13a, b, and d systems in routinely used mammalian cell lines
118 reported a low degree of off-target effects in eukaryotic cells (Abudayyeh et al., 2017; Cox et al.,
119 2017; Konermann et al., 2018). However, more recently, several groups reported cellular toxicity
120 and more pronounced off-target effects of CasRx, LwaCas13a, and PspCas13b in sensitive cell
121 types (Ai et al., 2022; Özcan et al., 2021), *in vivo* (Buchman et al., 2020), and when targeting
122 highly expressed transcripts ([Shi et al. 2023](#)).

123
124 To understand if this cellular toxicity is shared across Cas13 orthologs, we computationally
125 identified 46 novel Cas13d orthologs from recently reported prokaryotic genomes and
126 metagenomic contigs and screened them for target transcript knockdown activity and cytotoxic
127 effects in human cells. We identified DjCas13d, a highly efficient ortholog with minimal
128 detectable cellular toxicity when targeting highly expressed transcripts across multiple cell
129 types, including human embryonic stem cells, neural progenitor cells, and neurons.
130 Furthermore, we show that our CasRx-based guide design model extends to DjCas13d and
131 accurately selects highly efficient guides, illustrating its generalizability across effectors and cell
132 types. Overall, we advance the transcriptome engineering toolbox by developing a robust
133 Cas13d guide design algorithm based on a high-throughput guide screen
134 (<https://www.RNAtargeting.org>), and identifying a compact and high-fidelity Cas13d ortholog for
135 efficient RNA targeting. Finally, we outline a strategy to systematically develop and interpret
136 robust deep learning models for sequence-based classification.

137 Results

138 **Deep learning of Cas13d guide RNA efficiency based on large-scale transcript** 139 **essentiality screening**

140 In order to systematically understand factors impacting Cas13d guide efficiency, we generated a
141 library of more than 100,000 RfxCas13d (CasRx) guide RNAs and evaluated their efficiency in a
142 large-scale pooled screen. Reasoning that CasRx knockdown of essential transcripts would
143 lead to the depletion of highly effective guides due to reduced cellular proliferation, we selected
144 a set of 55 essential genes identified in three previously reported survival screens performed
145 with RNAi and CRISPR interference (CRISPRi) in K562 cells (Hart et al., 2015; Horlbeck et al.,
146 2016; Luo et al., 2008) for a proliferation-based survival screen. K562 cells were selected due to
147 their ease of use in pooled screens and our observation of variable CasRx-mediated
148 endogenous protein knockdown in this cell line (**Figures S1A, B**).

149
150 To perform the screen, we first generated stable K562 cell lines via transfection of an all-in-one
151 plasmid encoding the CasRx effector, PiggyBac transposase, and an antibiotic selection

152 cassette. Next, we designed CasRx guides that tile the 5' UTR, coding sequence (CDS), and 3'
153 UTR of the 55 essential transcripts with single nucleotide resolution. As controls, we designed
154 guides tiling 5 non-essential transcripts as well as 3,563 non-targeting guides. The effector cell
155 line stably expressing CasRx was transduced with a pooled lentiviral library containing all
156 144,745 guide RNAs. Cells were cultured for 14 days, after which we analyzed guide
157 abundances by NGS and computed a depletion ratio for each guide compared to its original
158 abundance in the input library (**Figure 1A**). Analysis of the cumulative distribution of guide
159 d14/input ratio demonstrated that the top 20th percentile of guides targeting essential transcripts
160 are clearly separated from guides targeting non-essential transcripts or non-targeting guides
161 (**Figure 1B**).

162
163 Essential transcripts may vary in their magnitude of impact on cell proliferation and survival
164 upon depletion. A transcript-level analysis of guide depletion confirmed this expectation (**Figure**
165 **S1C**). In order to compensate for this in our analysis going forward, we selected the most
166 effective guides for each individual transcript (see Methods for a full description of selection
167 parameters) as high efficiency guides. A heat map representation of the positions of these high
168 efficiency guides within each target transcript revealed a striking degree of clustering, leading to
169 guide hot spots and deserts along the transcript and clearly deviating from a random distribution
170 (**Figure 1C**). Multiple factors could be responsible for the observed clustering of high efficiency
171 guides, including sequence-, structure-, or position-based effects of the guide RNA or target
172 transcript.

173 174 **Prediction of CasRx guide activity based on guide RNA sequence alone**

175 We sought to systematically analyze these potential features that could distinguish high
176 efficiency Cas13d guides and develop computational algorithms to predict guide efficiency.
177 Initial analysis of the correlation of nucleotide identity with guide efficiency at each position
178 along the 30 nt spacer showed a preference for G and C at the direct repeat-proximal spacer
179 positions 15-24 (**Figure S2A**). Therefore, we reasoned that spacer sequence alone might be
180 predictive of guide efficiency when used as model input. We then developed a series of
181 computational models for prediction of guide efficiency based on one-hot encoding of the 30 nt
182 guide spacer sequence without manual sequence feature selection. To understand the impact
183 of computational model type, we systematically built and assessed the following models: 3
184 linear models employing logistic regression (Lasso Regression (L1), Ridge regression (L2) or
185 Elastic Net (EN)), 2 ensemble models (Random forest (RF) and Gradient-boosted tree (GBT))
186 and 2 deep learning models (convolutional neural network (CNN) and bidirectional long short-
187 term memory neural network (LSTM)) (**Figure 1D**).

188
189 All of these models were trained to classify high efficiency guides for target transcripts. Due to
190 the observed high degree of clustering of effective guides along a transcript (**Figure 1C**),
191 models that are tested on held-out guides from the same transcripts they were trained on would
192 potentially be subject to overfitting by learning the targeting hotspots specific to those
193 transcripts. To alleviate overfitting and ensure model generalizability to other transcripts, we
194 employed 9-fold cross-validation on the 54 target transcripts (leaving out *RPS19BP1* as it
195 clustered with non-essential transcripts (**Figure S1C**)), with models being trained and tested on

196 non-overlapping sets of transcripts. We compared the performance of all 7 models and
197 observed high model performance for the gradient-boosting tree (GBT) and the two deep
198 learning models based on Area Under the Receiver Operating Characteristic curve (AUROC),
199 which evaluates prediction accuracy for both the positive class (high efficiency guides) and the
200 negative class, and Area under the Precision-Recall Curve (AUPRC) metrics, which focuses
201 primarily on the prediction accuracy of the positive class (high efficiency guides), across all 9
202 fold splits (**Figure 1E**).

203
204 Overall, the CNN model performed best with a high AUROC of 0.845 (relative to a baseline of
205 0.5) and a high AUPRC of 0.541 (relative to a baseline of 0.18), so we chose this model for
206 further refinement and evaluation. The high prediction accuracy of this model based on the
207 spacer sequence alone indicates that sequence is a primary factor determining guide efficiency.
208 We further determined that the addition of target flanking sequences of varying length from 1-7
209 nt to the CNN model did not meaningfully improve model performance (**Figure S2B**), consistent
210 with our previous biochemical studies suggesting a lack of strong flanking sequence
211 requirements (Koner mann et al., 2018). To understand the minimal spacer length required for
212 accurate prediction, we computationally truncated the spacer sequence from the 3' end in the
213 CNN model input, and found only a minor impact on model accuracy until reaching a spacer
214 length of 24 nt, after which a gradual drop in AUROC and AUPRC was observed (**Figure S2C**).
215 We validated this experimentally, demonstrating decreasing target knockdown when using
216 guides shorter than 24 nt in spacer length (**Figure S2D**).

217 218 **Addition of secondary features improves guide efficiency prediction accuracy**

219 Beyond guide sequence alone, secondary guide attributes such as guide unfolding energy or
220 target site position (CDS or UTR) may impact guide performance. To understand their potential
221 contribution, we first evaluated the correlation of such secondary features with guide efficiency
222 (**Figure 1F schematics, S3A-F**). We found that higher predicted guide and target RNA
223 unfolding energy, implying more highly structured RNA sequences, were predictive of poor
224 guide efficiency. We also observed a preference for intermediate spacer GC content (45-55%),
225 guides targeting the coding region (CDS), as well as guides targeting regions conserved across
226 transcript isoforms.

227
228 As most of the secondary features investigated exhibited a modest correlation with guide
229 efficiency, we tested whether they would improve model performance when added to the spacer
230 sequence-only CNN model. When adding these features individually, we found that the guide
231 target site position had the most prominent effect, followed by target and guide RNA folding
232 energy (**Figure S3G**). The addition of spacer GC content did not significantly improve model
233 performance, consistent with our expectation that this feature has been successfully captured
234 by the spacer sequence-only CNN model. Sequentially including each secondary feature ranked
235 by their individual contribution into the sequence-only CNN model, we found that AUROC and
236 AUPRC were improved with each addition, leading to a final model with a very high average
237 AUROC of 0.875 and a high average AUPRC of 0.638 (**Figure 1F and S3H-J** for feature
238 variations). Adding the same set of secondary features also improved the GBT model (**Figure**

239 **S4**), the best performing model not based on deep learning, indicating the contribution of these
240 secondary features to guide efficiency.

241
242 One of the key applications of a predictive model like this one would be to accurately predict the
243 most effective guides in order to aid in guide and library design. The CNN model returns a float
244 score ranging from 0 to 1 for every guide, and different thresholds can be chosen for high
245 efficiency guide classification. To evaluate model performance for optimal guide selection, we
246 set a high model score threshold of 0.8 and plotted the true percentile rank distribution of the
247 guides above the score threshold. As expected, the guides were heavily skewed towards the
248 highest efficiency ranks, with a true positive ratio of 0.83 (83% being true high efficiency guides
249 (top 20th percentile)). Setting an even more stringent model score threshold to 0.9 further
250 increased the true positive ratio to 93% (**Figure S3K**).

251
252 **Model interpretation reveals favored sequence and secondary features of high efficiency**
253 **guides**

254 Having built high performance models that accurately predict efficient guides, we asked whether
255 these models could help us understand the features contributing to guide efficiency by using
256 three model interpretation methods. We first used an integrated gradients approach (IG)
257 (Sundararajan et al., 2017) to provide observability for our CNN model. We began with the
258 guide sequence preferences learned by the model, and IG analysis on each position in the
259 guide spacer sequence nominated a core region of position 15-24 as a major contributor to
260 guide efficiency (**Figure 2A**). Consistent with our original correlation analysis (**Figure S2A**), IG
261 analysis on each positional nucleotide in the guide sequence revealed a clear preference for an
262 alternating stretch of guanines, cytosines and guanines ($G_{15-18}C_{19-22}G_{23-24}$) in this core region
263 (**Figure 2B**).

264
265 To confirm the favored sequence features across models and model interpretation methods, we
266 further applied SHapley Additive exPlanations (SHAP), a game theoretic approach (Lundberg et
267 al., 2020) to our GBT model, and a similar sequence preference in the same core region was
268 observed (**Figures S5A, B**). In contrast, this unique sequence preference was not found for
269 Cas13a when we performed a correlational analysis of available datasets (Abudayyeh et al.,
270 2017; Metsky et al., 2022) (**Figure S6**). Indeed, no consistent sequence preference or core
271 region emerged across the Cas13a datasets analyzed, which could be due to intrinsic
272 enzymatic properties of Cas13a or limitations in the size of available datasets.

273
274 As our IG and SHAP analyses investigated each position in the guide sequence independently,
275 we further sought to determine the role of specific motifs (nucleotide combinations) in guide
276 efficiency. We employed Transcription Factor Motif Discovery from Importance Scores (TF-
277 MoDISco), an algorithm that identifies sequence patterns or motifs incorporated in deep learning
278 models by clustering important sequence segments based on per-position importance scores
279 (Shrikumar et al., 2018). We discovered a total of 14 distinct sequence patterns associated with
280 high efficiency guides from the CNN model, with the top 5 patterns shown in **Figure 2C**. As TF-
281 MoDISco was initially applied for the identification of transcription factor binding motifs, it is
282 designed to identify motifs in a position-independent manner. In our analysis, we noticed that all

283 identified patterns were anchored to a specific position centered around guide spacer
284 nucleotides 18-20 (**Figure S7A**), consistent with our prior observation of a core region.

285
286 Strikingly, all top 5 sequence patterns contained a cytosine at position 21, with a single guanine
287 at varying positions in the core region across the different patterns. Taken together, the
288 identified motifs can be summarized as **GN_xC₂₁** or **N_xC₂₁G** within the core region. Generally, the
289 patterns were sparse and characterized by just two dominant bases (one G and one C), in
290 contrast to the longer 10-base motif that the individual position-level analysis would have
291 suggested (**Figures 2B and S5B**). Consistent with our results above, an analysis of enriched
292 and depleted 3-mers in high efficiency guides across the spacer sequence revealed that
293 enriched 3-mers were again clustered in the core region (position 15-24) (**Figure S7B**). In
294 addition to the consistent finding of a prominent enrichment of C at position 21, they revealed a
295 preference for A or T intercalated with G and C (**Figures S7B, C**), a finding that was obscured
296 in the per-position analysis. Analysis of enriched and depleted 4-mers in high efficiency guides
297 also led to a similar finding (**Figure S7D**). A/T substitutions within the 10-base motif ($G_{15-18}C_{19-}$
298 $_{22}G_{23-24}$) (**Figure 2D**) and analysis of the GC content in the core region (**Figure 2E**) for high
299 efficiency guides further confirmed a preference for a medium GC content via A/T nucleotides at
300 the N positions of the key **GN_xC₂₁** or **N_xC₂₁G** motif.

301
302 Next, we used IG and SHAP to investigate the contribution of secondary features in the CNN
303 and GBT models. IGs revealed that targeting the beginning of the 5' UTR and the end of the 3'
304 UTR was the most disfavored, while targeting the coding region (CDS) was generally favored,
305 with a slight preference for the beginning of the CDS (**Figures 2F, G**). In agreement with our
306 correlation analysis, guide and target unfolding energy also had a relatively high impact on
307 guide efficiency, with lower unfolding energy favored by high efficiency guides (**Figures 2H, I**).
308 SHAP analysis on our GBT model showed a consistent direction of feature contribution to guide
309 efficiency (**Figure S5C**) and ranked spacer sequence composition as the most important
310 feature.

311
312 Taken together, our systematic model interpretation was consistent across models and analysis
313 approaches, was able to rank features by their contribution toward guide classification, and
314 significantly expanded our understanding of preferred longer-range sequence motifs that were
315 missed by simpler correlational analyses.

316 317 **Systematic validation of the guide efficiency model across 5 cell types with endogenous** 318 **protein knockdown**

319 Next, we sought to experimentally validate our model through CasRx-mediated knockdown of
320 cell surface markers, reasoning that an orthogonal readout to transcript essentiality and cell
321 survival would ensure generalizability of our model predictions to multiple readout modalities. To
322 this end, we performed a screen using a library of 3,218 guides tiling the transcripts of two cell
323 surface markers, *CD58* and *CD81*, with single-nucleotide resolution. 10 days after lentiviral
324 transduction of the guide library, cells were FACS sorted into 4 bins on the basis of target
325 protein expression level (**Figure 3A**) and the enrichment of individual guides in the top and
326 bottom bins (exhibiting the greatest or least magnitude of knockdown, respectively) was

327 assessed. We observed clear separation of the most efficient targeting guides from the non-
328 targeting guides based on the enrichment ratio, with zero non-targeting guides appearing in the
329 top 20th percentile of guide efficiency (**Figure 3B**).

330
331 We evaluated our CNN model's performance on this new dataset and found that an ensemble
332 CNN model comprising all 9 fold splits of the survival screen outperformed each individual split
333 model (**Figure S8A**) and achieved high prediction accuracy for both *CD58* (AUROC of 0.88 and
334 AUPRC of 0.66) and *CD81* (AUROC of 0.86 and AUPRC of 0.62) (**Figure 3C**). This
335 performance is comparable to the model accuracy on held-out essential transcripts from our
336 initial screen (**Figure 1F**), highlighting its generalizability. Compared with two existing Cas13d
337 guide design models (Wessels et al., 2020, Cheng et al. 2023), our model showed the highest
338 AUROC, AUPRC, and Spearman correlation. Importantly, we showed that at a 0.9 score cutoff,
339 our model exhibited a very high true positive ratio of 0.93 and 0.9 for *CD58* and *CD81*,
340 respectively, in contrast to the Wessels et al. model (0.52 for both *CD58* and *CD81*) and
341 DeepCas13 (0.38 for *CD58* and 0.35 for *CD81*) (**Figure 3C**). The far higher true positive ratio at
342 high score cutoffs underlines the superior utility of our model for key applications such as
343 predicting the top 3-10 guides per target transcript in individual targeting or library-based
344 screening approaches. Illustrating this use case, we examined the true percentile rank of the top
345 10 predicted high efficiency guides for *CD58* and *CD81*, showing that 10/10 guides for *CD58*
346 and 9/10 for *CD81* were highly effective (**Figure 3D**).

347
348 To assess generalizability to other cell types, we evaluated our model's performance on a
349 published CasRx guide tiling dataset (~3000 guides in HEK293FT cells from the Wessels et al.
350 training dataset). Our model showed high AUROC (0.85, 0.88 and 0.85 for *CD46*, *CD55* and
351 *CD71*, respectively), AUPRC (0.59, 0.59 and 0.67), Spearman correlation (0.67, 0.69 and 0.66),
352 and true positive ratio (0.76, 0.9 and 0.94 at a 0.9 score cutoff) (**Figure 3E**). Among the top 10
353 predicted high efficiency guides, 90% were highly efficient (falling into the top 20% percentile of
354 efficient guides) (**Figure 3F**). When compared against the Wessels et al. model on opposing
355 datasets (**Figure S8B**), our model showed significantly higher prediction accuracy using all
356 evaluation metrics (AUPRC: 0.617 vs 0.379; Spearman correlation r_s : 0.675 vs 0.391; AUROC:
357 0.873 vs 0.733; true positive ratio (0.9 cutoff): 87% vs 51%), further supporting the
358 generalizability and high performance of our model.

359
360 As a final test of the ability of our model to predict efficient guides for knockdown of desired
361 transcripts in different cell types, we selected 5 top scoring guides and 5 low scoring guides
362 (excluding the very bottom of our ranking) for two different transcripts (*CD59* and *CD146*), and
363 tested the knockdown efficiency of each guide in HeLa, U2OS, and A375 cells (**Figure 3G**).
364 Across all three cell lines, the top scoring guides showed very efficient target knockdown (72%-
365 98% with a median of 90%) while low scoring guides showed variable and significantly lower
366 levels of knockdown (6%-70% with a median of 35%), confirming the utility and generalizability
367 of our model across 5 cell types (K562, HEK293FT, HeLa, U2OS, and A375).

368
369 **Discovery of DjCas13d, a high-efficiency RNA targeting enzyme with minimal cellular**
370 **toxicity in human cells**

371 In genome engineering, two of the most important features are efficiency and specificity. A key
372 emerging limitation of several Cas13 systems is the induction, in certain contexts, of cellular
373 toxicity by its RNA trans-cleavage activity (Ai et al., 2022; Buchman et al., 2020; Özcan et al.,
374 2021), hampering their application as a generalizable transcriptome engineering tool. In the
375 context of this study, we also observed various degrees of cellular toxicity for CasRx when
376 paired with highly efficient guides in the A375 cell line (**Figure S9A**).

377
378 To address this, we reasoned that the evolutionary diversity of Cas13d enzymes may have
379 already developed solutions to these challenges. To develop a more broadly useful
380 transcriptome engineering tool, we sought to identify a Cas13d ortholog that combines the key
381 positive traits of CasRx, like its small size and high targeting efficiency, with low cellular toxicity.
382 We applied our previously described computational approach for Cas13d discovery (Konermann
383 et al., 2018) to an expanded database of metagenomic datasets and discovered 46 previously
384 uncharacterized Cas13d enzymes, expanding the known Cas13d family from 7 to 53 members
385 (**Figure 4A, Table S7**).

386
387 To evaluate these novel Cas13d enzymes for mammalian transcript knockdown, we
388 synthesized human codon-optimized constructs of each enzyme with NLS (nuclear localization
389 sequence) and NES (nuclear export sequence) fusions and measured their ability to knockdown
390 the mCherry reporter transcript using a matched guide array containing two mCherry targeting
391 guides. We identified 14 enzymes exhibiting >55% knockdown efficiency (**Figure 4B**) in this
392 reporter assay. Because reporter knockdown is often weakly predictive of Cas13 performance
393 on endogenous targets, we further tested the 14 orthologs on our shortlist for their knockdown
394 efficiency when targeted to the endogenous *CD81* transcript. With this more stringent test, 7
395 orthologs exhibited >50% knockdown efficiency (**Figure 4C**), and we focused on these for
396 further characterization.

397
398 Having identified this shortlist of the most efficient Cas13d enzymes, we next evaluated their
399 cytotoxic effects in human embryonic stem cells (hESC), since we previously observed issues in
400 this cell type with CasRx. When targeting the non-essential transcript *CD81* in this highly
401 sensitive cell type, we were able to observe a significant reduction in viable cells expressing
402 CasRx and most of the other Cas13d orthologs (**Figure 4D**), consistent with cytotoxic effects on
403 other sensitive cell types reported in the literature (Özcan et al., 2021). Strikingly, two of the
404 orthologs we tested (DjCas13d and Ga_0531) led to no detectable reduction of viable cell
405 counts (**Figure 4D**). Of those two, we chose DjCas13d for additional characterization given its
406 high knockdown efficiency (>80% in hESCs) (**Figure 4E**) and unusually small size (877aa,
407 compared to 967aa for CasRx) (**Figure 4C**).

408
409 In a further evaluation across three guides each for three transcripts in hESCs, DjCas13d
410 showed no significant effects on viable cell counts in contrast to CasRx, which caused
411 significantly reduced viable cell counts in eight out of nine guides (**Figure 4F**). In terms of
412 knockdown efficiency, DjCas13d showed high knockdown efficiency of >70% for most guides
413 tested (median of 71.5%) – efficiency that was comparable to CasRx (median of 77.4%) (**Figure**
414 **4F**).

415

416 **DjCas13d induces minimal cellular toxicity when targeting highly expressed transcripts**

417 Recent work ([Ai et al. 2022](#); [Shi et al. 2023](#)) and our results in stem cells (**Figure 4F**) highlighted
418 high target transcript abundance as a key variable for Cas13-mediated cellular toxicity in
419 addition to the importance of cell type. In our own experiments in hESCs, we also observed the
420 lowest survival rate for CasRx when targeting the most abundant transcript – *CD24* – while no
421 such impact was observed for DjCas13d (**Figure 4F**). In order to further compare CasRx and
422 DjCas13d under conditions known to promote cellular toxicity, we targeted three previously
423 described highly expressed transcripts (*ACTG1*, *HNRNPA2B1*, *FTH1*) ([Shi et al. 2023](#)) in
424 HEK293FT cells and confirmed a significant reduction of the number of viable cells when using
425 CasRx but not DjCas13d (**Figure 4G**, all guides significant at $P < 0.0001$). We targeted three
426 medium- and three low expression level transcripts, confirming that lower expression of the
427 target transcript alleviated the toxicity induced by CasRx (**Figure 4G**), consistent with initial
428 reports (Konermann et al., 2018). By contrast, we observed minimal impact on viable cell counts
429 when using DjCas13d to target any of these transcripts (**Figure 4G**), despite comparable
430 knockdown efficiency of DjCas13d (knockdown median of 88%) to CasRx (median of 84%).

431

432 In a second head-to-head comparison, we tested DjCas13d against the recently reported Cas7-
433 11 enzyme, which does not belong to the Cas13 family of CRISPR enzymes and was reported
434 to have no impact on cell viability due to its distinct RNA cleavage mechanism (Kato et al.,
435 2022; Özcan et al., 2021). We demonstrate that both DjCas13d and Cas7-11 have a
436 comparably low impact on cell viability and proliferation (90% median cell count for DjCas13d
437 across all targeting conditions, and 73% for Cas7-11) when targeting the same medium to
438 highly expressed transcripts - in stark contrast to CasRx (46% median cell count). However,
439 Cas7-11 suffered from diminished knockdown efficiency (median of 57%) compared to
440 DjCas13d and CasRx (median of 88% and 84%, respectively) (**Figure 4G**).

441

442 Overall, we conclude that DjCas13d combines the best features of CasRx and Cas7-11,
443 exhibiting low cellular toxicity and high knockdown efficiency. 84% of guides tested with
444 DjCas13d showed >80% survival rate and >60% knockdown, while only 32% of CasRx guides
445 and no Cas7-11 guides met these cutoffs.

446

447 **DjCas13d activity can be accurately predicted with our guide efficiency model**

448 Given that DjCas13d belongs to the same subtype of CRISPR effectors as CasRx, we next
449 sought to test whether our Cas13d guide design model could be successfully applied to this new
450 Cas13d ortholog. Encouragingly, our data in **Figure 4F** and **G** demonstrated high efficacy of
451 knockdown with guides recommended by the model when using DjCas13d across 12 transcripts
452 of different expression levels and in different cell types. To further explicitly validate the model
453 performance for DjCas13d, we selected a set of top and bottom scoring guides for a total of
454 eleven transcripts across a range of expression levels in hESCs, HeLa, and U2OS cell lines.
455 Across hESCs (**Figure 4H**) as well as HeLa and U2OS cells (**Figure 4I**), the predicted high
456 efficiency guides resulted in a significantly higher degree of protein knockdown (median of
457 73.9%) compared with low-scoring guides (median of 19.7%) (**Figures 4H, I**). Altogether, these
458 results demonstrate that our model generalizes to the novel DjCas13d ortholog, resulting in

459 reliable knockdown performance and lack of apparent cellular toxicity even in sensitive cell
460 types and for highly abundant transcripts. Given that the sequence divergence between
461 DjCas13d and CasRx (29.9%) is similar to the divergence between other Cas13d orthologs from
462 our new metagenomic mining (~29.4% on average), we expect that our guide design model
463 may generalize to other Cas13d effectors as well.

464

465 **DjCas13d exhibits high transcriptome-wide specificity**

466 The context-dependent cellular toxicity mediated by many Cas13 enzymes is hypothesized to
467 result from collateral cleavage of bystander transcripts ([Buchman et al. 2020](#); [Özcan et al. 2021](#);
468 [Ai et al. 2022](#); [Shi et al. 2023](#)). This is consistent with the observation that cellular viability and
469 proliferation are more noticeably impacted when targeting more abundant transcripts – which
470 would result in a larger number of activated Cas13 enzymes per cell and therefore more
471 potential collateral RNA cleavage.

472

473 To investigate this hypothesis and compare the collateral and off-target effects between CasRx
474 and DjCas13d, we performed RNA-seq two days after CasRx or DjCas13d-mediated
475 knockdown of *CD81* (307 Transcripts Per Million (TPM)), *FTH1* (1219 TPM) and *ACTG1* (3728
476 TPM) in HEK293FT cells (**Figure 5A**). Our transcriptome-wide analysis revealed significantly
477 more non-target transcripts affected by CasRx when targeting more highly expressed transcripts
478 (*ACTG1*>*FTH1*>*CD81*), indicating greater levels of collateral or off-target effects (**Figure 5A**). In
479 contrast, we observed minimal transcriptome-wide perturbation by DjCas13d apart from
480 knockdown of the intended target transcript (**Figure 5A**).

481

482 Next, we extended our RNA-seq analysis to assess consequences of CasRx and DjCas13d in
483 more sensitive hESC cells when targeting genes with high (*CD24*), medium (*CD81*), or low
484 (*TFRC*) expression levels. CasRx-mediated knockdown of high and medium expressed genes
485 resulted in rampant loss of cell viability, making transcriptome analysis impossible in many
486 samples. Consistent with the high survival of sensitive cell types following DjCas13d treatment
487 above, this toxicity was not observed for DjCas13d targeting the same transcripts. Similar to the
488 HEK293FT RNA-seq above, we observed a significant reduction in off-target transcriptome
489 perturbations when using DjCas13d (0 off-targets for most guides tested, with a modest 7 and
490 103 off-targets for the two guides targeting *CD24*) compared to CasRx (hundreds of off-targets
491 even when targeting low- and medium-expression transcripts, and rampant cellular toxicity
492 when targeting highly expressed transcripts) (**Figure 5B**).

493

494 Importantly, in order to rule out transcriptome-wide depletion that would be difficult to detect via
495 differential RNA-seq, we used defined concentrations of exogenous RNA spike-ins to assess
496 total RNA amount per cell. While CasRx showed a significant decrease in total RNA abundance
497 across guides targeting *CD71*, DjCas13d did not display significant global RNA depletion with
498 any guide/target tested, consistent with its low off-targets and low toxicity (**Figure S10A**). As an
499 additional measure of transcriptome integrity, we visualized total RNA extracted from these
500 samples and showed that while RNA integrity for DjCas13d was intact, CasRx targeting resulted
501 in the appearance of a smaller molecular weight band between the 28S and 18S for all targeting
502 guides (**Figure S10B**), which has also been noted by other groups (Shi et al., 2023).

503

504 To distinguish between guide-specific off-target effects and universal sequence-indiscriminate
505 collateral effects in our CasRx datasets, we analyzed the overlap between up- and down-
506 regulated transcripts among different guides, targets and cell types (**Figures S10C, D, E, F**).
507 We found a meaningful overlap between the significantly upregulated transcripts across
508 different CasRx conditions, with enrichment of the unfolded protein response signaling pathway,
509 suggesting that CasRx mediated non-target-specific collateral activity may stimulate generalized
510 cellular stress responses.

511

512 **DjCas13d is a effective tool for gene knockdown in many sensitive cell types**

513 Given the promise of DjCas13d as a high-fidelity and low-toxicity RNA targeting tool, we sought
514 to apply DjCas13d to RNA targeting in sensitive biological processes and therapeutically-
515 relevant cell types. Our demonstration of CasRx toxicity in hESC cells led us to assess
516 DjCas13d knockdown in the context of hESC differentiation into neuronal progenitor cells
517 (NPC), hematopoietic progenitor cells (HPC), and neurons. DjCas13d was delivered via an
518 inducible Piggybac system at the stem cell stage and induced during differentiation. In NPCs,
519 we targeted five transcripts including highly-expressed genes like *BSG* and *THY1*, and lower
520 expressed transcripts such as *CD46* with one or two top-scoring guides per gene. We observed
521 high cellular survival in all cases with no significant decrease relative to non-targeting
522 conditions, and effective knockdown efficiencies in most cases, with a median of 63% (**Figure**
523 **6A**). In HPCs, we observed 46-69% knockdown of the target proteins CD81 and TRFC in
524 DjCas13d-expressing cells with no detectable survival defect (**Figure 6B**). In both of these
525 cases, we confirmed that the expected markers of differentiation efficiency were not affected by
526 DjCas13d targeting (SOX1 and PAX6 for NPC, CD43 for HPC) (**Figures 11A,B**). Finally, we
527 differentiated hESCs to neurons using Neurogenin-2 (Ngn2) directed differentiation and
528 assessed DjCas13d's ability to knock down two proteins, CD81 and CD24, with 3 top-scoring
529 guides each. We observed uniform knockdown of approximately 50% in all cases (measured at
530 the protein level via FACS), coupled with high cell survival near 100% (median of 98%) (**Figure**
531 **6C**). Altogether, these data illustrate the broad applicability of DjCas13d across multiple target
532 genes in sensitive cell types of high biological and therapeutic interest.

533

534 To support easy use of both DjCas13d and CasRx for RNA targeting, we created a freely
535 accessible portal to run our model for Cas13d guide prediction on all human and mouse
536 transcripts and custom target sequences. This community resource is available at
537 <http://RNAtargeting.org>.

538 Discussion

539 In this study, we applied CasRx for large-scale screening across 127,000 guides against 55
540 target transcripts in human cells, a dataset that is >12 times larger than previous Cas13 guide
541 design studies ([Wessels et al. 2020](#); [Cheng et al. 2023](#)). Using this dataset, we developed a
542 highly accurate, deep learning-based Cas13d guide efficiency model to nominate highly efficient
543 guides for transcripts of interest. The model exhibits excellent performance across two screen
544 modalities, nine cell types, and two diverse Cas13d orthologs, illustrating its generalizability for

545 predicting highly effective guides across different contexts. The major factors contributing to our
546 model's generalizability include its primary reliance on the guide RNA spacer sequence - a cell
547 type-independent feature - as well as the 9-fold cross-validation of the model on non-
548 overlapping sets of transcripts, which alleviates overfitting to targeting hotspots specific to
549 certain transcripts.

550

551 Previous attempts to predict CRISPR guide efficiency have primarily relied on manual selection
552 of a limited set of guide sequence features combined with simpler machine learning models,
553 such as elastic nets (Horlbeck et al., 2016), SVM (Doench et al., 2016), or random forest
554 approaches (Wessels et al., 2020). More recently, deep learning models, which are able to learn
555 complex, high-order patterns and features automatically from raw data, have been employed to
556 predict guide efficiency for Cas9 activity (Chuai et al., 2018; Kim et al., 2019; Xue et al., 2019),
557 Cpf1 (Kim et al., 2018), base editors (Arbab et al., 2020; Koblan et al., 2021), Cas13a (Metsky
558 et al., 2022) and Cas13d ([Cheng et al. 2023](#)).

559

560 Here, we directly compared two deep learning models with linear and ensemble methods
561 (elastic nets, random forest, and gradient-boosted trees) for guide efficiency prediction, finding
562 that the deep learning model (CNN) outperformed the other approaches. This illustrates the
563 power of deep learning models in sequence-based prediction tasks due to its automatic feature
564 selection and ability to identify motifs or long-range interactions given a sufficiently large dataset
565 (>100,000 guides). Furthermore, we show that our model significantly outperforms the current
566 state-of-the-art models ([Wessels et al. 2020](#); [Cheng et al. 2023](#)) (**Figures 3C, S8B**).

567

568 While deep learning models can extract important higher-order features automatically from raw
569 inputs, the interpretation of feature contributions is challenging. Prior deep learning models for
570 Cas9 (Chuai et al., 2018; Xue et al., 2019) and other sequence-based applications (Alipanahi et
571 al., 2015; Kelley et al., 2016; Lanchantin et al., 2016) mainly employed neuron visualization
572 methods to unveil important motifs. These approaches are able to successfully identify patterns
573 recognized by individual filters, but can suffer from redundancy of the identified motifs. Recently
574 developed interpretation methods such as Integrated Gradients, SHAP, and TF-MoDISco, can
575 address these limitations and have begun to be applied to identify consolidated and non-
576 redundant motifs for transcription factor binding (Avsec et al., 2021). In this report, we evaluated
577 feature importance directly from the deep learning model using these new model interpretation
578 approaches. This allowed us to discover a core region at guide spacer position 15-24 with a
579 specific sequence composition predictive of high efficiency guides. Comprehensive motif
580 analysis revealed a preference for $GW_{1-4}C_{21}$ or $C_{21}W_{0-2}G$ motif. In contrast, analysis of base
581 preference at individual positions and correlation-based evaluation of feature importance
582 (Wessels et al., 2020) obscured this motif. This underscores the utility of the combination of
583 deep learning models that are able to learn higher order sequence features along with
584 advanced motif-discovery approaches for model interpretation such as TF-MoDISco used here
585 – the first time, to our knowledge, that such an approach has been applied to CRISPR guide
586 activity prediction models.

587


588 In addition to effective guide selection, cellular toxicity has emerged as a significant challenge
589 for Cas13 applications, effects likely mediated by off-target and/or collateral RNA cleavage
590 ([Buchman et al. 2020](#); [Özcan et al. 2021](#); [Ai et al. 2022](#); [Shi et al. 2023](#)). Initial reports
591 developing diverse Cas13 effectors for mammalian transcript knockdown demonstrated high
592 specificity and lack of apparent cellular toxicity in HEK293FT cells, plants, and animal embryos
593 (Abudayyeh et al., 2017; Cox et al., 2017; Konermann et al., 2018; Kushawah et al., 2020;
594 Mahas et al., 2019). However, several recent studies have reported marked cellular toxicity of
595 these effectors in other cell types or target contexts (Buchman et al., 2020; Özcan et al., 2021).
596

597 Two recent studies aiming to reconcile these reports concluded that collateral RNA cleavage by
598 Cas13 enzymes is correlated with the expression level of the target transcript, and that the
599 effect on cellular toxicity is dependent on the cell type ([Ai et al. 2022](#); [Shi et al. 2023](#)), indicating
600 that highly expressed transcripts and sensitive cell types are prone to Cas13-mediated collateral
601 cleavage and toxicity. Our data comparing CasRx's effect across cell types and endogenous
602 target RNAs with varying expression levels supports this conclusion. We reasoned that more
603 robust CasRx RNase activation upon higher target transcript levels would result in a greater
604 amount of collateral RNA cleavage, which in turn could activate cellular stress pathways and
605 lead to toxicity.
606

607 To advance Cas13 applications in sensitive cell types and therapeutic scenarios, our discovery
608 of the DjCas13d ortholog promises to address current limitations of both CasRx (context-
609 dependent cellular toxicity) and Cas7-11 (efficiency and size). DjCas13d exhibits minimal
610 cellular toxicity even in challenging conditions, and achieves high efficiency and transcriptome-
611 wide targeting specificity against highly expressed transcripts across various cell types. We
612 further demonstrate efficient and high-viability endogenous RNA targeting with DjCas13d in
613 hESC-derived neuronal progenitor cells (NPCs), hematopoietic progenitor cells (HPCs), and
614 neurons. Therefore, DjCas13d is poised to overcome the limitations of previous tools. Future
615 work characterizing mechanistic distinctions between CasRx and DjCas13d may reveal further
616 protein engineering opportunities.
617

618 Taken together, DjCas13d paired with our state-of-the-art Cas13d guide design model provides
619 a comprehensive solution for 3 key challenges in the RNA targeting toolbox by enabling high
620 efficiency, cell viability, and specificity. We further envision that the deep learning model
621 architecture, systematic feature engineering, and model interpretation approach outlined in this
622 study will be broadly applicable to other sequence-based tasks, such as the prediction of guide
623 RNA activities for newly discovered CRISPR enzymes, DNA/RNA modifications, and DNA/RNA-
624 protein interactions.
625
626

627 Figures




629 **Figure 1: Deep learning of Cas13d guide RNA efficiency based on large-scale transcript**
630 **essentiality screening**

631 **A.** Schematic of the pooled CasRx guide tiling screen for essential transcript knockdown as a
632 readout of per-guide knockdown efficiency. Over 127,000 targeting guide RNAs were included.


633 **B.** Cumulative distribution of the ratio of relative guide abundance at day 14 compared to the
634 input library across guides targeting essential gene transcripts (blue), non-essential gene
635 transcripts (orange), and non-targeting guides (green). The red dashed line indicates the ratio at
636 the top 20th percentile of essential transcript targeting guides. **C.** Heat map of the positional

637 distribution of high efficiency guides along each transcript. From here forward, high efficiency
638 guides are defined as the top 20% guides within each transcript with a d14/input ratio lower than
639 0.75 after essential off-target filtering. Heat map color indicates the number of overlapping high
640 efficiency guides at each nucleotide position along the transcript, and the inlaid histogram
641 depicts the observed frequency distribution of these data (blue) as compared to a random
642 distribution of 20% of guides in the library (orange curve). **D.** Schematic of the computational
643 algorithms assessed in this study to predict guide efficiency based on spacer sequence alone.

644 **E.** Comparison of prediction accuracy between linear, ensemble and deep learning models
645 across 9-fold splits of held-out transcripts. Averages of Area Under the Receiver Operating
646 Characteristic curve (AUROC) and Area Under the Precision-Recall Curve (AUPRC) across test
647 sets from all 9 folds are shown \pm SD. LR - L1, logistic regression with L1 regularization (Lasso
648 Regression); LR - L2, logistic regression with L2 regularization (Ridge regression); LR - EN,
649 logistic regression with elastic net regularization (Elastic Nets) ; GBT, Gradient-Boosted Tree;
650 RF, Random Forest classifier; CNN, Convolutional Neural Network; biLSTM, Bidirectional long
651 short-term memory neural network. Note that the baseline for AUPRC is equal to the fraction of
652 positive class (high efficiency guides), in this case 0.18. **F.** Secondary features were evaluated
653 for their ability to improve sequence-only model performance. Each secondary feature (or
654 feature group) was added to the CNN model sequentially, ordered by its individual contribution
655 to model performance in **Figure S3G**. AUROC and AUPRC (mean \pm SD) of all test sets from the
656 9-fold split of transcripts are shown.




657
 658 **Figure 2: Deep learning model interpretation reveals favored sequence motifs and**
 659 **secondary features of high efficiency guides**
 660 **A.** Evaluation of the importance of each position in the guide spacer sequence in the CNN
 661 model using Integrated Gradients (IG). Higher absolute gradient values indicate greater
 662 importance for predicting a high efficiency guide. The gray box highlights the identified core
 663 region (position 15-24). **B.** Evaluation of the importance of each positional nucleotide in the
 664 guide sequence in the CNN model by IG. **C.** Top 5 sequence patterns identified by TF-MoDISco
 665 (Transcription Factor Motif Discovery from Importance Scores) in the CNN model. Patterns are
 666 aligned to the 30 nt spacer according to the mode position of the seqlets (sequence regions with
 667 high importance based on IG scores) in each pattern (**Figure S7A**). **D.** Fraction of high
 668 efficiency guides that contain the 10-base motif shown in panel B and A/T substitutions within
 669 the 10-base motif. **E.** Fraction of high efficiency guides across different core region GC content.
 670 Guides were divided into eleven bins based on the GC content in their core region (position 15-
 671 24), and the fraction of high efficiency guides belonging to each bin is plotted. **F.** Contribution of
 672 target transcript region (5' UTR, CDS, or 3'UTR) to guide efficiency in the CNN model. The bar
 673 plots indicate average IGs of all test samples with different target position flags. **G.** Contribution
 674 of position within each transcript target region to guide efficiency in the CNN model. The scatter
 675 plots indicate individual IG values against individual input values across all test samples. The
 676 reference points are set to 0 for each transcript region. **H.** Contribution of predicted guide
 677 unfolding energy to guide efficiency in the CNN model. The reference point is set to 0. **I.**
 678 Contribution of predicted target unfolding energy to guide efficiency in the CNN model. The
 679 reference point is set to 0.




681 **Figure 3: Systematic validation of the guide efficiency model across 5 cell types with**
682 **endogenous protein knockdown**

683 **A.** Schematic of the pooled CasRx guide tiling screen targeting *CD58* or *CD81* transcripts in
684 K562 cells followed by flow cytometry-based readout of cell-surface CD58 or CD81 protein
685 abundance. **B.** Cumulative distribution of guide enrichment ratios for *CD58*, *CD81* and non-
686 targeting guide categories, calculated as the ratio of guide percentage in bin 1 (greatest
687 knockdown) relative to the sum in bin 1 and bin 4 (least knockdown). Red dashed lines indicate
688 the ratio for the top 20th percentile of targeting guides. **C.** Model comparison on *CD58* and
689 *CD81* guides. CNN, the ensemble CNN model built on the survival screen data in this work;
690 Wessels et al. model, a previously published CasRx random forest model (Wessels et al.,
691 2020); DeepCas13, a previously published CasRx deep learning model ([Cheng et al. 2023](#)).
692 Model performance is evaluated by AUROC, AUPRC, Spearman's correlation coefficient (r_s)
693 and true positive ratio at 0.8 and 0.9 model score cutoffs across guides targeting *CD58* (left
694 panel) and *CD81* (right panel). **D.** True percentile rank of the top 10 predicted high efficiency
695 guides for *CD58* and *CD81*. The red dashed line indicates the top 20th percentile of *CD58*- or
696 *CD81*-targeting guides. **E.** Performance of the ensemble CNN model on a published CasRx
697 guide tiling dataset of three CD transcripts (*CD46*, *CD55*, and *CD71*) in HEK293FT cells
698 (Wessels et al., 2020). Model AUROC, AUPRC, Spearman's correlation coefficient (r_s), and true
699 positive ratio at 0.8 and 0.9 model score cutoffs are shown for each transcript. **F.** True percentile
700 rank of the top 10 predicted guides by our model for three transcripts in a published CasRx
701 guide tiling dataset in HEK293FT cells (Wessels et al., 2020) predicted by the ensemble CNN
702 model. The red dashed lines indicate the top 20th percentile of targeting guides. **G.** Knockdown
703 efficiency of the predicted 5 top scoring guides and 5 low scoring guides for two transcripts
704 (*CD59* and *CD146*) measured by flow cytometry in HeLa, U2OS, and A375 cells. Heat map color
705 indicates the mean knockdown efficiency for each guide across $n = 3$ biological replicates. The
706 top scoring guides and low scoring guides were significantly different at $P < 0.0001$ for HeLa,
707 U2OS and A375 cells based on Welch's t test.



709 **Figure 4: Discovery of DjCas13d, a high-efficiency RNA targeting enzyme with minimal**
710 **cellular toxicity in human cells**


711 **A.** Phylogenetic tree of Cas13 enzymes including the expanded Cas13d subtype clade (yellow).
712 46 additional Cas13d orthologs were identified through mining of recent metagenomic datasets.
713 The 7 previously identified Cas13d orthologs including CasRx (red) are shown in bold text. The
714 newly discovered ortholog DjCas13d is shown in blue. All the ortholog sequences are provided
715 in Table S7. **B.** Evaluation of the knockdown efficiency of all Cas13d orthologs shown in panel A
716 on an mCherry reporter transcript in HEK293FT. Horizontal green dashed line denotes our
717 selected cutoff of >55% knockdown efficiency; the hits are color-coded for further study. **C.**
718 Evaluation of the knockdown efficiency of the selected 14 Cas13d orthologs on an endogenous
719 transcript, *CD81*, as measured by flow cytometry-based readout of protein abundance. The
720 horizontal green dashed line denotes a 50% knockdown efficiency cutoff. Cas13d enzymes are
721 plotted in order of their protein size on the x-axis (small to large). **D-E.** Evaluation of cell viability
722 (panel **D**) and knockdown efficiency (panel **E**) of cells expressing each of the top seven most
723 efficient Cas13d orthologs in H1 hESCs along with a *CD81*-targeting guide. The horizontal
724 green dashed line in panel E denotes an 80% knockdown efficiency cutoff. Orthologs are
725 ordered by their size and color-coded as in panel C. Values are shown as mean \pm SEM for $n = 3$
726 replicates. **F.** Evaluation of cellular viability (y axis) and knockdown efficiency (x axis) of
727 DjCas13d and CasRx across three transcripts in the hESC line, H1. Three top guides were
728 picked for each transcript based on the CNN model score. Each dot on the scatter plot
729 represents one guide's survival rate and knockdown (mean for $n = 3$ replicates). The dots are
730 colored by the effector used (CasRx: red, DjCas13d: blue), and the color gradients denote the
731 expression level of the target transcript relative to *GAPDH* (\log_2 relative expression) in the
732 hESC line H1 based on qPCR. The dashed box denotes guides with >80% survival rate
733 and >60% knockdown. 89% of DjCas13d guides are within the box while only 11% of CasRx
734 guides are within the box. **G.** Evaluation of cellular viability (y axis) and knockdown efficiency (x
735 axis) of DjCas13d, CasRx, and Cas7-11 across nine transcripts of different expression levels in
736 HEK293FT using the same spacer sequences across all three enzymes. Three top guides were
737 picked for each transcript based on the CNN model score. Each dot on the scatter plot
738 represents one guide's survival rate and knockdown (mean for $n = 3$ replicates). The dots are
739 colored by the effector used (CasRx: red, DjCas13d: blue, Cas7-11: grey), and the color
740 gradients denote the expression level (TPMs (transcript per million), $\log_2(\text{TPM}+1)$) of the target
741 transcript. As in panel F, the dashed box denotes guides with >80% survival rate and >60%
742 knockdown. 84% of DjCas13d guides are within the box while 32% of CasRx guides and 0
743 Cas7-11 guides are within the box. **H.** Knockdown efficiency of DjCas13d paired with 3 top
744 scoring guides and 3 low scoring guides from the CNN model prediction on nine transcripts of
745 different expression levels in H1 hESCs. Heat map color indicates the mean extent of
746 knockdown for each guide across $n = 3$ biological replicates. The top scoring guides and low
747 scoring guides were significantly different at $P < 0.0001$ based on Welch's t test. **I.** Knockdown
748 efficiency of DjCas13d paired with 5 top scoring guides and 5 low scoring guides from the CNN
749 model prediction on two transcripts (*CD59* and *CD146*) in Hela and U2OS cells. Heat map color
750 indicates the mean knockdown efficiency for each guide across $n = 3$ biological replicates. The
751 sets of top scoring guides and low scoring guides were significantly different at $P < 0.0001$ in
752 Hela and $P < 0.001$ in U2OS based on Welch's t test.



753

754 **Figure 5: DjCas13d exhibits high transcriptome-wide specificity**

755 **A.** Volcano plots of differential transcript levels between targeting guide conditions and non-
756 targeting (NT) guide control for CasRx (top) and DjCas13d (bottom) in HEK293FT cells using
757 two top-scoring guides for each target transcript (*CD81* (medium expression level), *FTH1* (high
758 expression level), and *ACTG1* (high expression level)). Red dots denote significantly affected
759 transcripts with adjusted p value < 0.1 and beta value > |0.5|. Green dots denote target
760 transcript isoforms, with darker green dots denoting the most abundant target transcript isoform,
761 and lighter green dots denoting other significantly changed target transcript isoforms. N=3
762 biological replicates. **B.** Volcano plots of differential transcript levels between targeting guide
763 conditions and non-targeting (NT) guide control for CasRx (top) and DjCas13d (bottom) in hESC
764 (H1) cells with two top-scoring guides for each target transcript (*TFRC* (low expression), *CD81*
765 (medium expression) and *CD24* (high expression)). Red dots denote significantly affected
766 transcripts with adjusted p value < 0.1 and beta value > |0.5|. Green dots denote target
767 transcript isoforms, with darker green dots denoting the most abundant target transcript isoform,
768 and lighter green dots denoting other significantly changed target transcript isoforms. N=3
769 biological replicates.



770

771 **Figure 6: DjCas13d enables toxicity-free RNA perturbation in various sensitive cell types**

772 DjCas13d-mediated RNA targeting in **A**: hESC-derived neuronal progenitor cells (NPCs); **B**:
 773 hESC-derived hematopoietic progenitor cells (HPCs); **C**: hESC-derived neurons. Left panel,
 774 schematic of the experimental workflow. Right panel, scatter plot of cellular viability (y axis) and
 775 knockdown efficiency (x axis) across five transcripts of different expression levels in NPCs and
 776 two transcripts of different expression levels in HPCs and neurons. Each dot on the scatter plot
 777 represents one guide's survival rate and knockdown (mean \pm SEM for $n = 3$ replicates). The
 778 dots are colored by the target transcript listed in the legend. The target transcripts are ranked by
 779 expression levels (high to low). The dots are colored by target transcripts. The black dashed line
 780 indicates a survival rate of 1.0 relative to the average of NT guides, and the shaded box
 781 indicates the SEM of the survival rate for NT guides.

782 Data and Code Availability

783 The model is freely accessible at <http://RNAtargeting.org>. The CasRx screen data and code for
784 this manuscript is available on Github https://github.com/jingyi7777/CasRx_guide_efficiency.
785 The RNAseq data is available at the NCBI Sequence Read Archive (SRA): PRJNA857683.

786 Acknowledgments

787 We thank the Konermann laboratory and Hsu laboratory for support and advice; A. Pawluk for
788 help with the manuscript; A. Kundaje and J. Zou for advice on deep learning models; J. Zou for
789 the recommendation of the LinearFold package; W. Zhuk for building the initial deep learning
790 model architecture; HK. Wayment-Steele for advice on RNA structure and energy prediction; A.
791 Shrikumar for advice on the implementation and application of TF-MoDISco to our analysis; The
792 Salk Institute NGS core and the Stanford Shared FACS facility for their support; and B. Hsu for
793 helping build the CasRx guide design website. K.F. was supported by a UCSD Eureka!
794 Scholarship for this work. S.K. is a Hanna Gray Fellow of the Howard Hughes Medical Institute,
795 a Chan Zuckerberg Biohub Investigator, and an Arc Institute Core Investigator. P.D.H. is
796 supported by the NIH (DP5 OD021369, R01 GM131073, R01 GM132465), DARPA, Emergent
797 Ventures, the Shurl and Kay Curci Foundation, and the Rainwater Charitable Foundation and
798 the Arc Institute.

799 Author Contributions

800 S.K. and P.D.H. conceived this study and supervised the design and analysis of all experiments.
801 J.W. and H.K. built the computational models, performed feature engineering, and implemented
802 model interpretation. S.K. and J.W. analyzed the NGS data from the screens and calculated
803 secondary features. J.W. performed the validation screen and individual guide testing in cancer
804 cells. J.W. created the Cas13d guide efficiency prediction tool and performed model
805 comparison. S.K. and P.D.H. computationally identified novel Cas13d orthologs. P.L. and E.W.
806 cloned all Cas13d orthologs and tested in HEK293FT. J.W. tested the top Cas13d orthologs in
807 stem cells. J.W., S.B., E.G., H.S., and E.K. cloned individual CasRx and DjCas13d guides. J.W.,
808 S.B., E.G., H.S., and E.K. performed individual guide testing in HEK293FT and stem cells. J.W.
809 performed RNA-seq experiments and analyzed the data with C. V. D.. J.W., H.S., E.K., S.B.,
810 and E.G. performed RNA knockdown experiments in stem cell-differentiated neuronal progenitor
811 cells, neurons, and hematopoietic progenitor cells. S.C. analyzed Cas13d ortholog sequences.
812 M.D. performed computational mining of additional Cas13 sequences and built the Cas13
813 phylogenetic tree. P.L. S.K., and P.D.H. adapted CasRx for high-throughput screening. S.K.,
814 K.F., P.L., and P.D.H. performed the cell proliferation screen. J.W., S.K., and P.D.H. wrote the
815 manuscript with input from all authors.

816 Competing Interest Statement

817 P.D.H. is a cofounder of Spotlight Therapeutics and Moment Biosciences and serves on their
818 boards of directors and scientific advisory boards, and is a scientific advisory board member to

819 Arbor Biotechnologies, Vial Health, and Serotiny. P.D.H. and S.K. are inventors on patents
820 relating to CRISPR technologies, including DjCas13d.

821 Methods

822 Plasmid design

823 For the CasRx expression vector, we designed a piggyBac-based all-in-one plasmid containing
824 the CasRx effector, piggyBac transposase, and antibiotic selection cassette: PB_EF1a-CasRx-
825 msfGFP-2A-Blast. The CasRx effector is fused to msfGFP at the C terminus and under the
826 control of a constitutive EF1a promoter. A nuclear localization signal SV40 NLS was added to
827 both the N and C terminus of CasRx-msfGFP. The antibiotic selection cassette, blasticidin S
828 deaminase, is linked with CasRx-msfGFP via a P2A self-cleaving peptide.

829
830 For the CasRx guide cloning vector, we designed a lentiviral vector: hU6-(CasRx DR)-EF1a-
831 Puro-WPRE. The CasRx DR is a 36-base direct repeat
832 (CAAGTAAACCCCTACCAACTGGTCGGGGTTTCAAAC) for CasRx pre-gRNA (Koner mann et
833 al., 2018). The 30 nt guide spacer sequence is cloned into the vector through Gibson cloning
834 using two BsmBI cleavage sites. For individual guide truncation and individual guide validation
835 experiments, we designed a piggyBac-based all-in-one plasmid containing the CasRx effector,
836 guide DR, piggyBac transposase, and antibiotic selection cassette: hU6-(CasRx DR)-TRE-
837 CasRx-msfGFP-EF1a-rtTA-2A-Puro-CMV-transposase.

838

839 Guide library design

840 For the survival screen, we selected 55 essential genes from the intersection of the essential
841 hits in three previous survival screens performed in K562 cells (Hart et al., 2015; Horlbeck et al.,
842 2016; Luo et al., 2008). We selected the major transcript isoform of these genes from the
843 Refseq database and designed guides that tile these transcripts with single nucleotide
844 resolution. A total of 127,071 targeting guides were generated for the 55 essential transcripts. In
845 addition, we designed 14111 guides tiling 5 non-essential control transcripts (*CTCF*, *SAGE1*,
846 *TLX1*, *DTX2*, *OR2C3*). Along with 3563 non-targeting guides, we constructed a pooled library of
847 144745 guides.

848

849 For the validation screen on cell surface markers, 3218 guides were designed that tiled *CD58*
850 transcripts (NM_001779.3, NM_001144822.2) and *CD81* transcripts (NM_004356.4,
851 NM_001297649.2) with single nucleotide resolution. The targeting guides were pooled with
852 1186 non-targeting guides to create the final library.

853

854 Guide library synthesis, cloning, and library amplification

855 For each guide spacer sequence in the guide library, we added a constant left overhang
856 (“AACCCCTACCAACTGGTCGGGGTTTCAAAC”) and a right overhang
857 (“TTTTTTTTGAATTCAAGCTTGGCGTAACTAGA”) to facilitate cloning. The resulting libraries
858 were synthesized as oligo pools by Twist Biosciences, and then PCR amplified using the primer
859 pair: Lib_F
860 (“TCTTGTGGAAAGGACGAAACACCGCAAGTAAACCCCTACCAACTGGTCGGGGTTT”) and

861 Lib_R
862 (“AGAGCTAGCCAGACGTGTGCTCTTCCGATCNNNNNNNNNTCTAGTTACGCCAAGCTTGA
863 ATTC”) (**Table S1**). The PCR reaction was performed using NEBNext High Fidelity PCR
864 Master Mix (NEB, catalog no. M0541L) for 20 cycles. The amplified library was gel-purified and
865 cloned into the BsmBI digested guide cloning vector (hU6-(CasRx DR)-EF1a-Puro-WPRE)
866 through Gibson assembly. The cloned guide library was then purified and concentrated by
867 isopropanol precipitation.

868
869 For guide library amplification, the library plasmid was electroporated to Endura
870 electrocompetent *E. coli* cells (Lucigen, catalog no. 60242-2) at 50–100 ng/ul. After
871 electroporation, cells were recovered in LB medium for 1h, and then plated on LB agar plates
872 with 100 ug/mL carbenicillin at 37°C for 12-14h. The colonies were then harvested at a
873 coverage of > 500 colonies per guide. The amplified guide library plasmid was extracted using
874 the Macherey-Nagel NucleoBond Xtra Maxi EF Kit (Macherey-Nagel, catalog no. 740424.10).
875 To determine guide RNA representation, we PCR amplified the guide region using customized
876 NGS primers containing Illumina adaptor sequences (**Table S1**). NextSeq sequencing was
877 performed to determine guide RNA representation in the guide library. We verified that the
878 library had >87% perfectly matching guides, <0.5% undetected guides, and a skew ratio (90th
879 percentile:10th percentile read number) of less than 10.

880 881 **Lentivirus production**

882 To produce lentivirus for the guide library, HEK293FT cells, purchased from Thermo Fisher (Cat
883 # R70007) were grown in DMEM supplemented with 10% FBS (D10 media) at 37 °C with 5%
884 CO₂. Cells were passaged at a ratio of 1:2 using TrypLE (Gibco) and seeded 20–24 h before
885 transfection at 1.8×10^7 cells per T225 flask. For lentiviral plasmid transfection, the guide library
886 plasmid was mixed with psPAX2 (Addgene, catalog no. 12260) and pMD2.G (Addgene, catalog
887 no. 12259) in Opti-MEM, and transfected to HEK293FT using Lipofectamine 2000 (Thermo
888 Fisher, catalog no. 11668027) and PLUS reagent (Thermo Fisher, catalog no. 11514015).
889 Medium was replaced 4 hours after transfection with fresh, prewarmed D10 medium. Two days
890 after the start of lentiviral transfection, the supernatant from the HEK293FT cells was harvested
891 and filtered using a 0.45um Stericup filter. The lentiviral titer was determined through spinfection
892 on K562 cells prior to the screen.

893 894 **Cell culture and CasRx cell line generation**

895 K562 cells were purchased from ATCC (CCL-243), and cultured in RPMI 1640 medium with
896 GlutaMAX™ supplement (Thermo Fisher, catalog no.61870036), 10% FBS, and Penicillin-
897 Streptomycin at 37 °C with 5% CO₂. To generate a stable CasRx-expressing K562 cell line, we
898 transfected K562 cells with the piggyBac-based all-in-one CasRx expression vector (PB_EF1a-
899 CasRx-msfGFP-2A-Blast) using Lipofectamine 3000 Transfection Reagent (Thermo Fisher,
900 catalog no. L3000001). Two days after transfection, we selected the cells with 10 µg/ml
901 blasticidin S (Thermo Fisher, catalog no. A1113903). After selection for 1-2 weeks, we checked
902 the percentage of CasRx-expressing cells using flow cytometry and confirmed that more than
903 95% of cells expressed CasRx-GFP.

904

905 **Survival screen**

906 The guide library for the survival screen was lentivirally transduced at MOI=0.2 by spinfection
907 into the stable CasRx-expressing K562 cell line. We ensured the guide library had a coverage
908 of >1000 cells per guide. Two days after transduction, cells were selected with 1 µg/ml
909 puromycin to ensure guide expression and further cultured for 14 days. Cells were harvested at
910 day 14 (end of the screen), and the genomic DNA was extracted using Zymo Research Quick-
911 gDNA MidiPrep (Zymo Research, cat. no. D4075). The guide region was PCR amplified using
912 customized NGS primers containing Illumina adaptor sequences. The resulting PCR products
913 were gel purified and quantified with Nanodrop and Qubit dsDNA HS Assay Kit (Thermo Fisher
914 Scientific, cat. no. Q32851). Pooled guide libraries were sequenced on Illumina NextSeq, with
915 80 cycles of read 1 (forward) and 8 cycles of index 1. Three biological replicates were
916 performed for the survival screen.

917

918 **Validation screen on *CD58* and *CD81***

919 The guide library for the validation screen on *CD81* and *CD58* was lentivirally transduced at
920 MOI=0.1 by spinfection into the stable CasRx-expressing K562 cell line. 45 million cells per
921 biological replicate were transduced to ensure coverage of >1000 cells per guide. After
922 spinfection, cells were selected with 1 µg/ml puromycin and further cultured for 10 days. At the
923 end of the screen, cells were divided into two pools and stained with *CD58* antibody (BD
924 Biosciences, catalog no. 564363) or *CD81* antibody (BD Biosciences, catalog no. 561958) and
925 analyzed using FACS Aria II (**Figure S11**). Following calibration with unstained controls, each
926 cell pool was sorted into four bins based on target gene expression level indicated by antibody-
927 conjugated fluorescence intensity. Specifically, cells were first gated by forward and side scatter
928 to select for live, single cells. Next, cells were gated on GFP to select for CasRx-expressing
929 cells. This final population was sorted into four bins based on the intensity of *CD58* or *CD81*
930 antibody-conjugated fluorescence intensity. As high efficiency guides were defined as the top
931 20% for each gene, we set the bin with the lowest target gene expression (bin 1) at 7-8%, which
932 is equal to the fraction of the target gene's high efficiency guide number in the whole library:
933 $1600 \times 0.2 / 4401$. The rest of the population was equally divided into three bins of the same size
934 (~30%). The genomic DNA for cells in each bin was extracted and sequenced as in the survival
935 screening. Four biological replicates were performed for the validation screen.

936

937 **Data preprocessing and definition of high efficiency guides**

938 For each guide RNA we calculated the fraction in the day 14 guide pool and the input library
939 pool. Guide efficiency was evaluated by the ratio of guide percentage in the day 14 pool to the
940 input pool (**Table S3**). Guides targeting each transcript were ranked based on their average
941 ratio across the three replicates, and we defined high efficiency guides for each transcript,
942 taking into account three parameters: 1) the top 20% guides per transcript; 2) no essential off-
943 targets predicted by BLAST (see the 'Off-target filtering' section below and **Figure S1D** for
944 details); and 3) with a d14/input ratio lower than 0.75 (the ratio at 5th percentile of the guides for
945 targeting control genes). Guides targeting the transcript *RPS19BP1* were excluded because
946 they clustered with non-essential controls (most guides were not effectively depleted in the
947 screen).

948

949 For the validation screen, we first filtered guides with less than 200 counts in all *CD58* bins and
950 *CD81* bins. Less than 1.5% of guides were removed by this filter. We then calculated each
951 guide's distribution across the 4 bins and used the ratio of guide percentage in bin 1 (greatest
952 knockdown) to the sum of its percentage in bins 1 and 4 (least knockdown) for evaluation of
953 guide efficiency. We then ranked guides within each gene based on their average ratio of the
954 four replicates, and we defined the top 20% guides for each gene as high efficiency guides.
955

956 **Off-target filtering**

957 We performed BLAST to identify potential off target matches for our guides. As the first 24
958 nucleotides from the 5' end of the CasRx guides were shown to be most indicative of guide
959 targeting ability (**Figure S2C**), we took the first 24 nucleotides of each guide as BLAST input.
960 BLAST was performed using a generous E value of 1 ($e=1$) against the Gencode V33 database.
961 BLAST results were parsed and off target genes were identified as those with up to three
962 mismatches to the guide input. To check the essentiality of the off-target genes, we made an
963 essential gene list by combining the essential gene hits from the three previous survival screens
964 in K562 cells and we compared the off-target genes with the essential gene list. Guides with
965 predicted off-targets in essential genes were filtered, as we reasoned they may interfere with the
966 interpretation of our survival screen readout. For our survival screening, 6790 guides were
967 filtered and 120281 guides remained for further analysis (**Figure S1D**, Table S4). For the
968 validation screen, the filtered dataset is provided in Table S5.
969

970 **Analysis of the positional distribution of high efficiency guides**

971 For each transcript, we calculated the number of high efficiency guides overlapping each
972 position on the transcript, and plotted the results using a heatmap. We further summarized the
973 distribution of high efficiency guides across all transcripts and positions with a histogram. In
974 theory, a particular nucleotide position would have at most 30 guides covering it, so the number
975 of efficient guides ranges from 0 to 30 for each position. We compared the results with a
976 randomly sampled distribution, which is simulated using 100 random samplings of 20% of the
977 guides in the library. In theory, the randomly sampled distribution would show a peak at 6
978 ($30 \times 20\%$), which agrees with our simulation results.
979

980 **Data splits**

981 For model hyperparameter tuning and evaluation, we split our 54 essential transcripts into 9
982 folds, each containing a unique and non-overlapping set of 6 test transcripts. The 54 transcripts
983 were distributed evenly across the 9 folds according to their high efficiency guide percent to
984 make the 9-fold split balanced. Using the predefined transcript splits, we performed 9-fold cross-
985 validation to tune model hyperparameters and compare prediction accuracy between models.
986

987 **Feature calculation and model inputs**

988 For the sequence input, each 30 nt guide spacer was one-hot encoded into four binary vectors
989 of length 30 to represent the nucleotide identity at each position.

990 To predict guide unfolding energy, we used LinearFold, a linear-time RNA secondary structure
991 prediction algorithm (Huang et al., 2019) on the full-length guide sequence (36nt DR +30nt

992 spacer). We started with the default parameters and the CONTRAfold v2.0 model (Do et al.,
993 2006; Lorenz et al., 2011; Wayment-Steele et al., 2020) provided by the LinearFold software at
994 <https://github.com/LinearFold/LinearFold>. We subtracted the predicted MFE (minimum free
995 energy) with the baseline energy (MFE of the unstructured guide with the 30 nt spacer unfolded)
996 to calculate guide unfolding energy. We also tested the Vienna RNAfold model in LinearFold as
997 a comparison. To determine whether using the ensemble guide unfolding energy instead of
998 MFE could improve model prediction, we further tested three RNA structure prediction
999 algorithms (Contrafold2, Eternafold, Vienna) wrapped by Arnie
1000 (<https://github.com/DasLab/arnie>) to calculate the ensemble guide unfolding energy with the
1001 partition function (Do et al., 2006; Lorenz et al., 2011; Wayment-Steele et al., 2020). For the
1002 Vienna package, we tested different temperature(T) settings: 37°C , 60 °C, and 70 °C. In our
1003 final model, we used the guide unfolding energy calculated by LinearFold’s default CONTRAfold
1004 v2.0 model as it improved model prediction accuracy to the greatest extent.

1005 To calculate target unfolding energy, we first used LinearFold’s CONTRAfold v2.0 model to
1006 predict MFE of the native local target region using the local target sequence. We then predicted
1007 MFE of the guide unwound local target region by supplying the algorithm with the constraint that
1008 the 30 nt guide-binding site is unpaired. (This can be achieved by feeding in an additional
1009 constraint structure with the guide-binding site annotated with “.”). We then subtracted the
1010 former MFE (MFE of the native target region) by the latter (MFE of the guide unwound target
1011 region) to estimate local target unfolding energy. The local target region was defined as the 30
1012 nt guide-binding site with 15 nt flanking sequence on both sides. Flanking sequences of different
1013 lengths were compared, and the length 15 was chosen for the final model as it improved model
1014 prediction accuracy to the greatest extent.

1015
1016 To calculate the percentage of isoforms targeted by each guide, we obtained all transcript
1017 isoforms for each gene from the Refseq database and evaluated the percentage of isoforms
1018 matched for each 30nt guide target (using perfect matches).

1019
1020 To calculate the three position flags, we obtained Refseq’s annotations of the 5’ UTR, CDS, or
1021 3’ UTR region for our target transcripts. Guides that target the 5’ UTR, CDS, or 3’ UTR region
1022 have a flag value of 1 for that correspondent feature, and 0 for the other two flag features. To
1023 calculate the three position floats (5’ UTR position,CDS position,3’ UTR position), we calculated
1024 the relative position of the guide target site in the 5’ UTR, CDS, or 3’ UTR region. Guides
1025 located out of the region have a flag value of 0 for the correspondent feature.

1026 1027 **Model architecture**

1028 *Sequence-only models*

1029 For linear models and ensemble models, the one-hot encoded guide sequence was flattened
1030 and converted to $30 \times 4 = 120$ flag features. The features are then fed into the models to generate
1031 the output. For the CNN model, the one-hot encoded guide was treated as a 4-channel image,
1032 and a few 1D convolutional layers were applied to generate a feature map, which was flattened
1033 and passed to a dense layer to generate the final output. For the biLSTM model, the guide
1034 sequence was treated as a sentence with four characters, and two LSTMs, each processing the

1035 input sequence in one direction (forward or backward), were applied to generate sequence
1036 representations. The resulting vectors were merged, flattened, and passed to a dense layer to
1037 generate the final output.

1038
1039 *Full model with secondary features*

1040 For the CNN model with secondary features, the one-hot encoded guide was passed to a few
1041 convolutional layers as in the sequence-only model. The output from the CNN layers was
1042 flattened and concatenated with the normalized secondary features. The concatenated feature
1043 vector was sequentially passed to a dense layer, a recurrent dense layer and a final dense layer
1044 of 1 unit to generate the output. All dense layers use leaky ReLU as the activation function. The
1045 CNN layer kernel size, unit number, layer number and the dense layer unit number were defined
1046 after hyperparameter tuning.

1047 For the Gradient-boosted classification tree, the one-hot encoded guide sequence was flattened
1048 and converted to $30 \times 4 = 120$ flag features. The sequence features are concatenated with the
1049 normalized secondary features, and then fed into the model to generate output.

1050
1051 **Model training, hyperparameter tuning and evaluation**

1052 All models were trained to solve a binary classification task – predicting high efficiency guides,
1053 and the model output is the probability that a guide is a high efficiency guide.

1054 The linear models and ensemble models were trained in scikit-learn 0.24 and the deep learning
1055 models (LSTM and CNN) were trained in TensorFlow 2.3.1. For the deep learning models, we
1056 used binary cross-entropy as the loss function and applied the Adam optimizer for model
1057 training. Early stopping was used to prevent model overfitting.

1058 For all models, the prediction accuracy is evaluated by AUROC (Area Under the Receiver
1059 Operating Characteristic curve) and AUPRC (The Area Under Precision-Recall Curve).

1060
1061 To tune hyperparameters and evaluate model performance, we used 9-fold cross-validation
1062 over the hyperparameter space. For linear models and ensemble models, we used the
1063 “GridSearchCV” function in scikit-learn to perform a grid search over the hyperparameter set.
1064 For deep learning models, we used the Hyperband tuner in TensorFlow to select top models
1065 quickly by filtering poor models during training.

1066
1067 The hyperparameter sets for all models are listed below:

- 1068 • logistic regression with L1 regularization: regularization strength - logarithmic in (10^{-5} , 10^5)
- 1069 • logistic regression with L2 regularization: regularization strength - logarithmic in (10^{-5} , 10^5)
- 1070 • logistic regression with elastic net regularization: regularization strength - logarithmic in (10^{-4} ,
1071 10^4), L1 ratio - equally spaced from 0.1 to 1.
- 1072 • Gradient-boosted classification trees: number of trees –
1073 [100,200,400,800,1000,1200,1500,1800,2000], maximum depth of a tree – [2,4,8], the number of
1074 features to consider when looking for the best split - all, $\sqrt{n_features}$, $\log_2(n_features)$.
- 1075 • Random forest (RF): number of trees – [100,200,400,800,1000,1200,1500,1800,2000], number of
1076 features to consider when looking for the best split - all, $\sqrt{n_features}$, $\log_2(n_features)$.
- 1077 • Long short-term memory recurrent neural network (LSTM): LSTM units - [16, 32,64,128], dense
1078 layer units – [8, 16, 32], recurrent dense layer number – [0,1,2,3], dropout rate - [0.0, 0.1, 0.25]

- 1079 • Convolutional neural network (CNN): CNN layer kernel size – [3,4,5], CNN units- [8,16,32,64],
1080 CNN layer number – [3,4,5], dense layer units - [8,16,32,64], recurrent dense layer number –
1081 [0,1,2,3]

1082

1083 For all models, we chose the hyperparameter set with the highest average AUROC across all
1084 test sets in the 9-fold splits, and evaluated the final model performance using both the average
1085 AUROC and average AUPRC across test sets.

1086

1087 **Secondary feature selection**

1088 For the CNN model, we added each secondary feature individually to guide sequence features
1089 and calculated the change in model performance. We selected features that successfully
1090 improved model performance, and added these features sequentially upon guide sequence
1091 features to check feature redundancy. We also tried removing individual features from the final
1092 model to confirm the necessity of the features.

1093 For the Gradient-boosted tree, besides the above methods, we also used Boruta, an all-relevant
1094 feature selection method that aims to find all features useful for prediction (Kursa et al., 2010).
1095 We implemented it using BorutaPy, the Python implementation of Boruta
1096 (https://github.com/scikit-learn-contrib/boruta_py) on our Gradient-boosted tree.

1097

1098 **Model interpretation and feature contributions**

1099 For the CNN model, we applied “Integrated Gradients” (IG) to investigate feature contributions
1100 in the model. “Integrated Gradients” is an attribution method that evaluates feature importance
1101 by integrating the gradient of output to input features along the straightline path from the
1102 baseline input to the actual input value (Sundararajan et al., 2017). Due to the non-linearity of
1103 the deep learning model, we applied “Integrated Gradients” to the best-performing individual
1104 CNN model on CD genes rather than the ensemble model. To compute integrated gradients, we
1105 first set all-zero baselines for the sequence input, position flags and position floats, and used
1106 average baselines for other features. Next, we generated a linear interpolation between the
1107 baselines and the inputs using 50 steps. We then computed gradients using the
1108 “tf.GradientTape” function in TensorFlow for the interpolated points, and approximated the
1109 gradients integral with the trapezoidal rule. To evaluate the relative importance of each position
1110 on the guide, we averaged the absolute integrated gradient values at each position across all
1111 test sequences. To evaluate the contribution of each nucleotide at each position, we averaged
1112 the integrated gradients for that nucleotide across all test sequences.

1113 For the Gradient-boosted tree, we applied SHAP (SHapley Additive exPlanations) to investigate
1114 feature contributions in the model. SHAP is a game theoretic approach that estimates how each
1115 feature contributes to the model output by providing the SHAP value for each input feature
1116 (Lundberg et al., 2020). We implemented the SHAP package from
1117 <https://github.com/slundberg/shap>, and applied it to our Gradient-boosted tree. To evaluate the
1118 relative importance of each position on the guide, we averaged the SHAP values at each
1119 position across test sequences. To evaluate the contribution of each nucleotide at each position,
1120 we averaged the SHAP values for that nucleotide across test sequences.

1121

1122 **Cas13a guide sequence contribution to guide efficiency**

1123 We analyzed three Cas13a guide efficiency datasets: 1) the Luciferase knockdown dataset
1124 containing 186 LwaCas13a guides for *Gaussia* luciferase (Gluc) and 93 guides for *Cypridina*
1125 Luciferase (Cluc) (Abudayyeh et al., 2017); 2) the endogenous gene knockdown dataset
1126 containing 93 LwaCas13a guides for each of *KRAS*, *PPIB* and *MALAT1* (Abudayyeh et al.,
1127 2017); and 3) the ADAPT dataset containing 85 perfect match LwaCas13a guides for virus
1128 detection (Metsky et al., 2022). We calculated the Pearson correlation between each nucleotide
1129 at each position with guide efficiency to evaluate the sequence contribution.

1130

1131 **Motif discovery**

1132 For motif discovery, we used TF-MoDISco (Transcription Factor Motif Discovery from
1133 Importance Scores), an algorithm that discovers motifs by clustering important regions in
1134 sequences using per-base importance scores (Shrikumar et al., 2018). We implemented TF-
1135 MoDISco from <https://github.com/kundajelab/tfmodisco> using the integrated gradients of all high
1136 efficiency guides in our training data as input. We ran TF-MoDISco with a sliding window size of
1137 7 and a flank length of 2. For final motif processing, we trimmed the clustered motifs to a
1138 window size of 6, added an initial flank length of 2 and a final flank length of 3 to get the final
1139 motifs. The top 5 active motifs are picked and aligned to the 30 nt spacer according to the mode
1140 position of sequences in each motif.

1141

1142 **Nmer analysis**

1143 To identify enriched or depleted positional nmers, we divided our survival screen data to 9 folds
1144 as in the model training workflow and calculated the ratio of all possible positional nmers'
1145 percentage in high efficiency guides to non-high efficiency guides in the training set and test set,
1146 respectively, for each fold. We identified enriched (or depleted) nmers based on their ratio in the
1147 training set with a predefined ratio cut-off. We selected the nmers identified as enriched (or
1148 depleted) across all folds, and ranked them by their average percent in high efficiency guides in
1149 the test sets across all folds. The initial ratio cut-off is set as 2 for enriched nmers and 0.5 for
1150 depleted nmers. The cut-off is adjusted during the nmer identification process so that the
1151 percent of guides with enriched nmers are ~20% and the percent of guides with depleted nmers
1152 are ~40%. We mainly focused on 3-mers and 4-mers in this paper.

1153

1154 **Final model and model testing on the validation screens**

1155 We chose the CNN model as our final model after hyperparameter tuning and model
1156 comparison. We re-trained the model using all of the survival screen data. To prevent
1157 overfitting, we split out a validation set during model training as in the previous 9-fold cross-
1158 validation split. We built 9 individual models using different validation sets from the 9-fold split of
1159 essential transcripts, and we compared their performance on the two cell surface markers,
1160 *CD58* and *CD81*. We further built an ensemble model that averaged the prediction of all the
1161 individual models. We found that the ensemble model outperformed all individual models on the
1162 two CD genes, so we set the ensemble CNN model as our final model. As a comparison, we
1163 also retrained the best non-deep learning model, the Gradient-boosted tree (GBT), using all of
1164 the survival screen data. We tested the model on the two CD genes and evaluated model
1165 performance using AUROC and AUPRC.

1166

1167 **Model comparison with Wessels et al. model and DeepCas13**

1168 We tested the performance of the Random forest model from Wessels et al. on our CD genes
1169 and essential genes using the web server <https://cas13design.nygenome.org> (Wessels et al.
1170 [2020](#); Guo et al. [2021](#)). We evaluated the model performance using AUROC, AUPRC,
1171 Spearman's correlation coefficient, r_s and true positive ratios at 0.8 and 0.9 model score cutoffs.
1172 As the Random forest model is designed for 23 nt long guides, we extended the guides from
1173 their model output to 30 nt (extends toward the 3' end) to be in accordance with our screen
1174 data. For comparison, we retrieved the CasRx guide tiling screen dataset on three genes,
1175 *CD46*, *CD55*, and *CD71*, from Wessels et al. and tested our model's performance. We adjusted
1176 the guide length to 23 nt in our model to be in accordance with their screen data, and we set the
1177 top 20% guides for each gene as "high efficiency guides". The model performance was also
1178 evaluated by AUROC, AUPRC, Spearman's correlation coefficient, r_s and true positive ratios at
1179 0.8 and 0.9 model score cutoffs.

1180

1181 We tested the performance of DeepCas13 ([Cheng et al. 2023](#)) on our CD genes using the web
1182 server <http://deepcas13.weillab.org>. We evaluated the model performance using AUROC,
1183 AUPRC, Spearman's correlation coefficient, r_s and true positive ratios at 0.8 and 0.9 model
1184 score cutoffs.

1185

1186 **Cas13d guide efficiency prediction tool and website**

1187 A website-based Cas13d guide efficiency prediction tool was developed using our CNN model
1188 for Cas13d guide design across model organism transcriptomes and custom RNA sequences.
1189 For model organism Cas13d guide design, we precomputed the Cas13d guide efficiency for all
1190 coding and non-coding genes of each model organism. Briefly, reference transcriptome
1191 sequences and annotations were obtained from the UCSC Table Browser (Karolchik et al.,
1192 2004) with the NCBI RefSeq track. All possible 30 nt Cas13d guide spacers were extracted from
1193 the transcriptome sequences with single nucleotide resolution. Secondary features were
1194 calculated for each guide as described in the '**Feature calculation and model inputs**' section
1195 above. The final CNN model was applied to all guides for prediction of their efficiency, and the
1196 guides were ranked within each gene based on the model prediction scores.

1197

1198 For custom sequence guide design, all possible 30 nt Cas13d guide spacers are extracted from
1199 the input custom RNA sequences with single nucleotide resolution. Guide unfolding energy and
1200 target unfolding energy are calculated as described in the '**Feature calculation and model**
1201 **inputs**' section above. A CNN model that uses guide sequence, guide unfolding energy and
1202 target unfolding energy as inputs, trained on the survival screen dataset, is applied to the
1203 custom sequence guides for prediction of their efficiency. Guides are ranked based on the
1204 model prediction scores.

1205

1206 The Cas13d guide efficiency prediction tool is freely available on a public, user-friendly website:
1207 <https://www.RNAtargeting.org>.

1208

1209 **Computational identification of novel Cas13d orthologs through metagenomic database** 1210 **mining**

1211 We applied our previously described pipeline for novel CRISPR effector discovery (Koneremann
1212 et al., 2018) to incompletely assembled metagenomic contigs in addition to whole genome,
1213 chromosome, and scaffold-level prokaryotic and metagenomic sample assemblies from the
1214 NCBI Genome database (<https://www.ncbi.nlm.nih.gov/>), the Gigadb repository
1215 (<http://gigadb.org/>), as well as the JGI Genome portal (<https://genome.jgi.doe.gov/portal/>).
1216 Putative effectors encoded near identified CRISPR arrays (<kb distance) were assigned to
1217 previously identified Cas13 families via tBLASTn analysis, where a bit score of at least 60 to any
1218 prior Cas13 subfamily member was required for cluster assignment. As a second round of
1219 discovery independent of CRISPR array identification, tBLASTn was performed on all original
1220 and predicted Cas13d effectors from the first round against all public metagenome whole
1221 genome shotgun sequences without predicted open reading frames (ORFs) from all three
1222 sources listed above. New full-length homologs and homologous fragments were aligned using
1223 Clustal Omega and clustered using PhyML 3.2 (Guindon et al., 2010). All the Cas13d ortholog
1224 sequences are provided in **Table S7**.

1225

1226 **Construction of Cas13 phylogenetic tree**

1227 A custom sequence database of bacterial isolate and metagenomic sequences was constructed
1228 by aggregating publicly available sequence database, including NCBI, UHGG (Almeida et al.,
1229 2021), JGI IMG (I.-M. A. Chen et al., 2021), the Gut Phage Database (Camarillo-Guerrero et al.,
1230 2021), the Human Gastrointestinal Bacteria Genome Collection (Forster et al., 2019), MGnify
1231 (Mitchell et al., 2020), Youngblut et al animal gut metagenomes (Youngblut et al., 2020),
1232 MGRAST (Meyer et al., 2008), and Tara Oceans samples (Sunagawa et al., 2015). Cas13
1233 sequences from other Cas13 families were identified by searching representative members of
1234 each clade (Cas13a/b/bt/c/x/y) against a collection of protein representatives (clustered at 30%
1235 identity) derived from the custom sequence database using hmmsearch from the hmmer
1236 package (*HMMER*, n.d.). Selected Cas13a, Cas13b, Cas13c, Cas13d representatives were
1237 LbuCas13a, BzoCas13b, AspCas13c, and CasRx respectively. The Cas13bt representative was
1238 collected from (Kannan et al., 2022), and the Cas13X and Cas13Y representatives were
1239 collected from (Xu et al., 2021). All hits that met $E < 1e-6$ and were 75%-125% the length of the
1240 representative sequence were retained. Sequences were assigned to the best matching
1241 representative. Sequences were then clustered at the 50% identity level along 80% of both
1242 sequences using the mmseqs package (Steinegger & Söding, 2017). Sequences were then
1243 aligned using the MAFFT algorithm mafft-linsi (Katoh et al., 2002). PhyML was used to generate
1244 phylogenetic trees with default parameters (Guindon et al., 2010). Trees were visualized using
1245 the ggtree package in R (Yu, 2020).

1246

1247 **Cloning of Cas13d orthologs and Cas7-11**

1248 For initial testing and efficiency screening, human codon optimized Cas13d sequences, flanked
1249 by two nuclear localization or export sequences, were cloned into a backbone derived from
1250 pXR001: EF1a-CasRx-2A-EGFP (Addgene #109049) to replace the CasRx coding sequence.
1251 Guide sequences targeting mCherry or *CD81* were cloned into a backbone derived from
1252 pXR003: CasRx gRNA cloning backbone (Addgene #109053) with 5' full-length direct repeat
1253 (DR) sequences for each Cas13d ortholog. For testing the seven high efficiency Cas13d
1254 orthologs in stem cells, the Cas13d coding sequences and respective mature DR guide scaffold

1255 sites were cloned into the inducible piggyBac-based all-in-one plasmid containing the Cas13d
1256 effector, guide DR, piggyBac transposase, and antibiotic selection cassette: hU6-DR-TRE-
1257 Cas13d-T2A-msfGFP-EF1a-rtTA-T2A-Puro-CMV-transposase. Human codon optimized
1258 DisCas7-11 protein sequence and the mature DR guide scaffold with golden gate sites were
1259 PCR amplified from Addgene plasmids # 172507 and #172508, a gift from Omar Abudayyeh &
1260 Jonathan Gootenberg, and cloned to the constitutive piggyBac-based all-in-one backbone
1261 plasmid as mentioned before. Guide spacers were position matched to CasRx and DjCas13d's
1262 guide spacers and were cloned into the backbone plasmid using Golden Gate cloning. All
1263 individual guide sequences are provided in **Table S6**.

1264

1265 **Cell culture for individual guide testing**

1266 HEK293FT cells were purchased from Thermo Fisher (Cat # R70007) and grown in DMEM
1267 supplemented with 10% FBS (D10 media) at 37 °C with 5% CO₂. Cells were passaged at a
1268 ratio of 1:2 using TrypLE (Gibco). Hela and A375 cells were gifts from the Howard Chang lab
1269 and Scott Dixon lab, respectively. They were both cultured in DMEM supplemented with 10%
1270 FBS (D10 media) at 37 °C with 5% CO₂. Cells were passaged at a ratio of 1:2 using TrypLE
1271 (Gibco). U2OS cells were a gift from the Chang lab and grown in McCoy's 5A (modified)
1272 Medium (Thermo Fisher, catalog no. 11668027) supplemented with 10% FBS at 37 °C with 5%
1273 CO₂. Cells were passaged at a ratio of 1:2 using TrypLE (Gibco). Stem cell line H1 were
1274 purchased from WiCell (Cat # WA01). Cells were maintained in mTeSR™ Plus media (Catalog
1275 # 100-0276, STEMCELL Technologies) on Matrigel-coated 6-well plate and passaged 1:12 with
1276 ReLeSR™ (Catalog # 05872, STEMCELL Technologies) every four days.

1277

1278 **Transfection of human cell lines**

1279 For initial testing and efficiency screening of Cas13d orthologs, HEK293FT cells were plated at
1280 20,000 cells per well in a 96-well plate, then transfected at >80% confluence with 192 ng
1281 Cas13d-2A-EGFP plasmid, 192 ng of crRNA expression plasmid, and 12 ng of mCherry
1282 expression plasmid using Lipofectamine 2000. Cells were harvested 48 hours after transfection
1283 for flow cytometry analysis of mCherry expression. For CD81 knockdown experiments,
1284 HEK293FT cells were transfected with 200 ng Cas13d-2A-EGFP plasmid and 200 ng guide
1285 RNA expression plasmid using Lipofectamine 2000. Cells were harvested 48 hours after
1286 transfection for staining and flow cytometry analysis of CD81 expression.

1287

1288 For experiments comparing CasRx, DjCas13d, and Cas7-11 in HEK293FT cells, cells were
1289 plated at 16,000 cells per well in a 96-well plate and transfected at > 80% confluence with 100
1290 ng of all-in-one PiggyBac plasmids containing CasRx, DjCas13d, or Cas7-11 using
1291 Lipofectamine 2000 (Life Technologies). Cells were selected with 1 µg/ml puromycin 24h after
1292 transfection. 24 hours after selection, cells were harvested for RNA extraction and downstream
1293 processing.

1294

1295 For individual guide testing in Hela cells, low passage cells were plated at a density of 15,000
1296 cells per well in a 96-well plate and transfected at > 80% confluence with all-in-one PiggyBac
1297 plasmids containing CasRx or DjCas13d using FuGENE® HD Transfection Reagent (E2311,
1298 Promega) according to the manufacturer's protocol. Cells were selected with 1 µg/ml puromycin

1299 and induced with Doxycycline (D3072, Sigma) for CasRx or DjCas13d expression 48h after
1300 transfection. Flow analysis was performed seven days after induction.

1301

1302 For individual guide testing in U2OS cells, low passage cells were plated at a density of 15,000
1303 cells per well in a 96-well plate and transfected at > 80% confluence with all-in-one PiggyBac
1304 plasmids containing CasRx or DjCas13d using ViaFect™ Transfection Reagent (E4981,
1305 Promega) according to the manufacturer's protocol. Cells were selected with 0.75 µg/ml
1306 puromycin and induced with Doxycycline (D3072, Sigma) for CasRx or DjCas13d expression
1307 48h after transfection. Flow analysis was performed seven days after induction.

1308

1309 For individual guide testing in A375 cells, low passage cells were plated at a density of 25,000
1310 cells per well in a 96-well plate and transfected at > 80% confluence with all-in-one PiggyBac
1311 plasmids containing CasRx using TransIT-X2 (MIR 6003, Mirus) according to the
1312 manufacturer's protocol. Cells were selected with 0.5 µg/ml puromycin and induced with
1313 Doxycycline (D3072, Sigma) for CasRx expression 48h after transfection. Flow analysis was
1314 performed seven days after induction.

1315

1316 For enzyme comparison and individual guide testing in H1 cells, low passage cells were
1317 passaged with Accutase (Innovative Cell Technologies) and plated into a Matrigel-coated 96-
1318 well plate with mTESR media containing ROCK inhibitor Y-27632 (10 µM, Abcam) at 30,000
1319 cells per well one day before transfection. On day 1, cells were transfected at > 80% confluence
1320 with all-in-one PiggyBac plasmids containing different Cas13d orthologs using FuGENE® HD
1321 Transfection Reagent (E2311, Promega) according to the manufacturer's protocol. Cells were
1322 selected with 0.5 µg/ml puromycin 48h after transfection. 5-7 days after selection, Cas13d
1323 expression was induced with Doxycycline (D3072, Sigma). Flow cytometry analysis was
1324 performed three days after induction.

1325

1326 For RNAseq experiments in H1 cells, low passage cells were passaged with Accutase
1327 (Innovative Cell Technologies) and plated into Cultrex (R&D Systems 343400502)-coated 96-
1328 well plates with mTESR media containing ROCK inhibitor Y-27632 (10 µM, Abcam) at 25,000
1329 cells per well one day before transfection. On day 1, cells were transfected at > 80% confluence
1330 with all-in-one PiggyBac plasmids containing different Cas13d orthologs using FuGENE® HD
1331 Transfection Reagent (E2311, Promega) according to the manufacturer's protocol. Cells were
1332 split and selected with 0.75 µg/ml puromycin 24h after transfection. Puromycin concentration
1333 was increased to 1ug/ml the next day. 72h after transfection, cells were harvested for RNA
1334 extraction and downstream processing.

1335

1336

1337 **Staining and flow cytometry**

1338 For cell surface protein staining, cells were harvested and dissociated with TrypLE, followed by
1339 two washes in cold FACS buffer (DPBS + 2 mM EDTA + 0.02% BSA), and then blocked with
1340 Human TruStain FcX (Biolegend) for 10 minutes. Cells were then stained with target antibodies
1341 for 1 hour at 4°C in the dark, followed by two washes using the FACS buffer, and then analyzed
1342 by flow cytometry.

1343

1344 For intracellular staining, cells were dissociated with Accutase and resuspended in DMEM/F12
1345 with GlutaMAX (ThermoFisher, Cat #10565018) with 20% trypsin inhibitor. Cells were then fixed
1346 with Cytofix/Cytoperm solution (BD) at 4°C for 20 minutes, followed by washes with Perm/Wash
1347 solution (BD). Cells were then stained with target antibodies for 45 minutes at 4°C in the dark,
1348 followed by two washes with the FACS buffer, and then analyzed by flow cytometry.

1349

1350 **RT-qPCR**

1351 Cells were lysed with BME-supplemented RLT buffer and total RNA was extracted with the
1352 RNeasy Plus 96 Kit (Cat #74192, QIAGEN). The extracted RNA was then reverse transcribed
1353 using RevertAid RT Kit (Thermo Fisher, Cat # K1691) with random hexamer primers at 25°C for
1354 5 min, 42°C for 60 min, and 70°C for 5 min. qPCR was then performed using Taqman Fast
1355 Advanced Master Mix (Thermo Fisher, Cat # 4444965) and Taqman probes for GAPDH control
1356 (Thermo Fisher, Cat # 4326317E) and target genes (IDT, custom gene expression assays).
1357 Custom Taqman probe and primer sets were designed to amplify target regions spanning the
1358 guide target sites. qPCR was performed in 384-well plates using the LightCycler 480 Instrument
1359 II (Roche). Target gene expression change was calculated relative to non-targeting controls
1360 using the ddCt method.

1361

1362 **Cell viability assays**

1363 For cell viability assays in HEK293FT, cells were plated at 9,000 cells per well in a 96-well plate
1364 the day before transfection. Cells were transfected with 100 ng of all-in-one PiggyBac plasmid
1365 containing constitutive CasRx, DjCas13d, or Cas7-11 using Lipofectamine 2000 (Life
1366 Technologies). 72 hours after transfection, cell viability was measured using WST-1 reagent
1367 (5015944001, Sigma) with an incubation time of 2 hours and measurement of absorbance at
1368 440nm. Cell viability of targeting guide groups for each effector was compared relative to the
1369 corresponding non-targeting guide group. Three biological replicates were performed.

1370

1371 To measure cell viability in stem cells, Hela, U2OS and A375 cells, cells were transfected with
1372 the inducible all-in-one PiggyBac plasmids containing inducible CasRx, DjCas13d, or other
1373 Cas13d orthologs. After selection for plasmid integration with 1 µg/ml puromycin for 5-7 days,
1374 cells were induced for effector (CasRx, DjCas13d or other Cas13d orthologs) expression using
1375 Doxycycline (D3072, Sigma). 3-5 days after induction, flow analysis was performed to quantify
1376 the percent of cells expressing the effector in each experimental group using the GFP reporter.
1377 The GFP+ percentage of cells with targeting guide groups for each effector was normalized to
1378 that of the corresponding non-targeting guide group for evaluation of cell viability upon target
1379 RNA knockdown. Three biological replicates were performed.

1380

1381 To measure cell viability in stem cell derived NPCs, HPCs, or neurons, we transfected stem
1382 cells with the inducible all-in-one PiggyBac plasmids containing inducible DjCas13d and
1383 selection with 1 µg/ml puromycin for 7 days to ensure plasmid integration. Differentiation
1384 procedures were then initiated and cells were induced for DjCas13d expression using
1385 Doxycycline (D3072, Sigma) at the middle time point of differentiation. 5-7 days after induction,
1386 flow analysis was performed to quantify the percent of cells expressing the effector in each

1387 experimental group using the GFP reporter. The GFP+ percentage of cells with targeting guide
1388 groups for each effector was normalized to that of the corresponding non-targeting guide group
1389 for evaluation of cell viability upon target RNA knockdown. Three biological replicates were
1390 performed.

1391

1392 **RNA-seq library preparation and sequencing**

1393 For HEK293FT cells, total RNA was extracted with the RNeasy Plus 96 Kit (Cat #74192,
1394 QIAGEN) 48h after transfection. For H1 cells, cell numbers were counted and normalized
1395 between different samples (different effectors, guides and replicates) 72h after transfection, and
1396 total RNA was extracted with the RNeasy Plus 96 Kit (Cat #74192, QIAGEN). Stranded mRNA
1397 libraries were prepared using the NEBNext II Ultra Directional RNA Library Prep Kit (NEB, Cat#
1398 E7760L) and NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB, Cat #E7490). The
1399 libraries were sequenced on a partial NovaSeq lane with 150 nt paired end reads. ~20M reads
1400 were demultiplexed per sample.

1401

1402 **RNA-seq analysis and pathway analysis of CasRx off targets**

1403 Sequencing reads were aligned to the hg38 Ensembl transcriptome using Kallisto (Bray et al.,
1404 2016). Mapping was carried out using default parameters except for a b value (number of
1405 bootstraps) of 100. Differential transcript expression was performed with Sleuth (Pimentel et al.,
1406 2017) using triplicates to compare between targeting and non-targeting conditions. Significantly
1407 differentially expressed transcripts were defined as having an adjusted p value < 0.1 and a beta
1408 value > 0.5. Volcano plots were generated in R using the package EnhancedVolcano (Blighe et
1409 al., 2019). Pathway analysis of CasRx off targets was performed using Enrichr (E. Y. Chen et
1410 al., 2013; Kuleshov et al., 2016; Xie et al., 2021) with the Molecular Signatures Database
1411 (MSigDB).

1412

1413 **RNA-seq Spike-In for total RNA quantification**

1414 To quantify total RNA amount accurately and determine if uniform transcriptome depletion has
1415 occurred following CasRx- or DjCas13-mediated transcriptome targeting, an equal amount of
1416 ERCC RNA Spike-In Mix (ThermoFisher, Cat #4456740) was added to the total RNA extracted
1417 from cell number-normalized H1 samples using the recommended dilution ratio before library
1418 preparation. After library preparation and NGS sequencing, the ratio of experimental reads to
1419 spike-in reads was calculated for all samples, and then normalized to the ratio of control
1420 samples (non-targeting guides) to get the total RNA amount relative to NT.

1421

1422 **RNA integrity analysis**

1423 To examine RNA integrity, electrophoresis was performed on the extracted RNA and the
1424 electrophoresis graphs were visualized on high sensitivity RNA chips using either Bioanalyzer
1425 (Agilent 2100 Bioanalyzer, G2939BA) (for experiments in HEK293FT) or TapeStation (Agilent
1426 4200 TapeStation system, G2991AA) (for experiments in H1).

1427

1428

1429 **Stem cell differentiation to NPC, HPC, neurons and RNA targeting experiments**

1430 For RNA targeting experiments in NPC and HPC, human embryonic stem cells (hESCs, H1 line,
1431 WiCell) were first transfected with inducible piggyBac-based all-in-one DjCas13d plasmids
1432 containing a puromycin resistance gene as mentioned above. For RNA targeting experiments in
1433 neurons, H1s were first transfected with inducible piggyBac-based all-in-one DjCas13d plasmids
1434 containing neomycin resistant gene by replacing the puromycin resistance gene in the
1435 piggyBac-based all-in-one DjCas13d plasmid with a neomycin resistance gene. After selection
1436 for plasmid integration with 1 µg/ml puromycin (NPC and HPC) or 100 µg/ml G418 Sulfate
1437 (neurons) for 7 days, differentiation procedures were performed as outlined below.

1438
1439 For differentiation to NPC, stem cells were passaged with Accutase (Innovative Cell
1440 Technologies) and plated at 30,000 cells per well into Matrigel-coated 96-well plates with N2B27
1441 media (DMEM/F12 (Thermo Fisher) + N2 (100x, Thermo Fisher) + B27 without vitamin A (50x,
1442 Thermo Fisher)) containing ROCK inhibitor Y-27632 (10 uM, Abcam) and bFGF (40 ng/mL,
1443 Corning). The following day (day 0), media was replaced with N2B27 media containing AZD-
1444 4547 (50 nM, Abcam, Cat# ab216311), LDN-193189 (250 nM, Sigma, Cat# SML0559), A83-01
1445 (250 nM, Sigma, Cat# SML0788), and XAV-939 (3 uM, Abcam, Cat# ab120897) to achieve dual
1446 SMAD and Wnt inhibition. Media was changed daily. On day 3, AZD-4547 was removed. On
1447 day 4, cells were passaged with Accutase (Innovative Cell Technologies) at 1:3 and plated
1448 again onto Matrigel-coated 96-well plates in N2B27 media containing ROCK inhibitor Y-27632
1449 (10 uM, AbAcam), LDN-193189 (250 nM, Sigma, Cat# SML0559), A83-01 (250 nM, Sigma,
1450 Cat# SML0788), and XAV-939 (3 uM, Abcam, Cat# ab120897). Media was replaced the next
1451 day with N2B27 containing LDN-193189 (250 nM, Sigma, Cat# SML0559), A83-01 (250 nM,
1452 Sigma, Cat# SML0788), and XAV-939 (3 uM, Abcam, Cat# ab120897). Media was changed
1453 daily and cells were induced for DjCas13d expression using Doxycycline (D3072, Sigma) on
1454 day 5. On day 8, all drugs were removed and the media was changed with N2B27 only
1455 (DMEM/F12 + N2 (100x) + B27 without vitamin A (50x)). On day 10, the cells were assayed for
1456 target knockdown and NPC marker expression (Pax6 and Sox1) using flow cytometry.

1457
1458 For differentiation to HPC, stem cells were passaged with ReLeSR (StemCell Technologies)
1459 and plated at ~40 colonies per well into Matrigel-coated 12-well plates with mTesR media
1460 (StemCell Technologies) containing ROCK inhibitor Y-27632 (10 uM, Abcam). The following day
1461 (day 0), media was replaced with 2 mL Hematopoietic Media A (STEMdiff Hematopoietic Basal
1462 Media (StemCell Technologies) with STEMdiff Hematopoietic Supplement A (200x, StemCell
1463 Technologies)). On day 2, a half-media change with Hematopoietic Media A was performed. On
1464 day 3, the media was fully replaced with 2 mL Hematopoietic Media B (STEMdiff Hematopoietic
1465 Basal Media (StemCell Technologies) + STEMdiff Hematopoietic Supplement B (200x,
1466 StemCell Technologies). On day 5, there was a half-media change with Hematopoietic Media B,
1467 and cells were induced for DjCas13d expression using Doxycycline (D3072, Sigma). On day 7
1468 and day 10, 1 mL fresh Hematopoietic B media was added but no media was removed. On day
1469 12, the cells were assayed for target knockdown and HPC marker expression (CD43) using flow
1470 cytometry.

1471
1472 For differentiation to neurons, hESCs (H1) were passaged with Accutase (Innovative Cell
1473 Technologies) and plated at 12,000 cells per well into Cultrex (R&D Systems 343400502)-

1474 coated 96-well plates with mTeSR media (StemCell Technologies) containing ROCK inhibitor Y-
1475 27632 (10 uM, Abcam). The following day cells were infected with lentivirus containing a
1476 doxycycline-inducible Ngn2 cassette in mTeSR media (StemCell Technologies) containing
1477 polybrene (10 mg/mL, Santa Cruz Biotechnology sc-134220). Following infection, media was
1478 changed daily to mTeSR media (StemCell Technologies). When cells reached 70% confluency,
1479 they were passaged with Accutase (Innovative Cell Technologies) and re-plated at 12,000 cells
1480 per well into Cultrex-coated 96-well plates with mTeSR media (StemCell Technologies)
1481 containing ROCK inhibitor Y-27632 (10 uM, Abcam). The day of passage was designated as
1482 day 0 of the differentiation protocol. The following day (day 1), media was replaced with mTeSR
1483 media (StemCell Technologies). On day 2, cells were induced for Ngn2 and DjCas13d
1484 expression using 2 ug/mL Doxycycline (2 ug/mL, Sigma D3072). On day 3, media was replaced
1485 with neural induction media (NIM, DMEM/F12 (Gibco 11330032) + Penicillin-Streptomycin
1486 (Gibco 15140122) + Doxycycline (2 ug/mL, Sigma D3072) + Laminin (1.2 ug/mL, Sigma L4544)
1487 + Insulin (5 ug/mL, Roche 11376497001) + BSA (10 mg/mL, Sigma A4161) + Apo-transferrin
1488 (10 mg/mL, Sigma T1147) + Putrescine (1.6 mg/mL, Sigma P57800) + Progesterone (0.00625
1489 mg/mL, Sigma P8783) + Sodium selenite (0.00104 mg/mL, S5261) + BDNF (10 ug/mL, Sigma
1490 B3795) + Puromycin (10 ug/mL, Life Technologies A1113803)). Media was changed daily. After
1491 3 days of puromycin selection, cells were passaged with Accumax (Innovative Cell
1492 Technologies) and plated at 87,500 cells per well with neural maturation media (Neurobasal
1493 differentiation media (Neurobasal Media (Gibco 21103049) + DMEM Media (Gibco 10569010) +
1494 HEPES (0.5x, Gibco 15630130) + Penicillin-Streptomycin (Gibco 15140122) + Glutamax (1 mM,
1495 Gibco 35050061)) + Doxycycline (2 ug/mL, Sigma D3072) + Laminin (2.4 ug/mL, Sigma L4544)
1496 + BDNF (10 ug/mL, Sigma B3795) + dbCAMP (49.14 ug/mL, Sigma Aldrich D0627) + B27 with
1497 vitamin A (1x, Gibco 17504044) + N-acetyl cysteine (5 ug/mL, Sigma A9165) containing ROCK
1498 inhibitor Y-27632 (10 uM, Abcam). Media was changed daily. On day 8, media was replaced
1499 with neural maturation media containing AraC (2.4 ug/mL, Sigma Aldrich C1768) to remove any
1500 post-mitotic neurons from the culture. On day 11, the cells were assayed for target knockdown
1501 using flow cytometry.

1502
1503
1504
1505

1506 References

- 1507 1. Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J.
1508 J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., Lander, E. S., Voytas, D. F.,
1509 Ting, A. Y., & Zhang, F. (2017). RNA targeting with CRISPR–Cas13. *Nature*, *550*(7675),
1510 280–284.
- 1511 2. Abudayyeh, O. O., Gootenberg, J. S., Franklin, B., Koob, J., Kellner, M. J., Ladha, A.,
1512 Joung, J., Kirchgatterer, P., Cox, D. B. T., & Zhang, F. (2019). A cytosine deaminase for
1513 programmable single-base RNA editing. *Science*, *365*(6451), 382–386.
- 1514 3. Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox,
1515 D. B. T., Shmakov, S., Makarova, K. S., Semenova, E., Minakhin, L., Severinov, K.,
1516 Regev, A., Lander, E. S., Koonin, E. V., & Zhang, F. (2016). C2c2 is a single-component
1517 programmable RNA-guided RNA-targeting CRISPR effector. *Science*, *353*(6299).
1518 <https://doi.org/10.1126/science.aaf5573>
- 1519 4. Ai, Y., Liang, D., & Wilusz, J. E. (2022). CRISPR/Cas13 effectors have differing extents
1520 of off-target effects that limit their utility in eukaryotic cells. *Nucleic Acids Research*.
1521 <https://doi.org/10.1093/nar/gkac159>
- 1522 5. Alipanahi, B., DeLong, A., Weirauch, M. T., & Frey, B. J. (2015). Predicting the sequence
1523 specificities of DNA- and RNA-binding proteins by deep learning. In *Nature*
1524 *Biotechnology* (Vol. 33, Issue 8, pp. 831–838). <https://doi.org/10.1038/nbt.3300>
- 1525 6. Almeida, A., Nayfach, S., Boland, M., Strozzi, F., Beracochea, M., Shi, Z. J., Pollard, K.
1526 S., Sakharova, E., Parks, D. H., Hugenholtz, P., Segata, N., Kyrpides, N. C., & Finn, R.
1527 D. (2021). A unified catalog of 204,938 reference genomes from the human gut
1528 microbiome. *Nature Biotechnology*, *39*(1), 105–114.
- 1529 7. Arbab, M., Shen, M. W., Mok, B., Wilson, C., Matuszek, Ż., Cassa, C. A., & Liu, D. R.
1530 (2020). Determinants of Base Editing Outcomes from Target Library Analysis and
1531 Machine Learning. *Cell*, *182*(2), 463–480.e30.
- 1532 8. Avsec, Ž., Weilert, M., Shrikumar, A., Krueger, S., Alexandari, A., Dalal, K., Froepf, R.,
1533 McAnany, C., Gagneur, J., Kundaje, A., & Zeitlinger, J. (2021). Base-resolution models
1534 of transcription-factor binding reveal soft motif syntax. *Nature Genetics*, *53*(3), 354–366.
- 1535 9. Blighe, K., Rana, S., & Lewis, M. (2019). EnhancedVolcano: Publication-ready volcano
1536 plots with enhanced colouring and labeling. *R Package Version*, *1*(0).
- 1537 10. Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016). Erratum: Near-optimal
1538 probabilistic RNA-seq quantification. *Nature Biotechnology*, *34*(8), 888.
- 1539 11. Buchman, A. B., Brogan, D. J., Sun, R., Yang, T., Hsu, P. D., & Akbari, O. S. (2020).
1540 Programmable RNA Targeting Using CasRx in Flies. *The CRISPR Journal*, *3*(3), 164–
1541 176.
- 1542 12. Camarillo-Guerrero, L. F., Almeida, A., Rangel-Pineros, G., Finn, R. D., & Lawley, T. D.
1543 (2021). Massive expansion of human gut bacteriophage diversity. *Cell*, *184*(4), 1098–
1544 1109.e9.
- 1545 13. Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., Clark, N. R., &
1546 Ma'ayan, A. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment
1547 analysis tool. *BMC Bioinformatics*, *14*, 128.
- 1548 14. Chen, I.-M. A., Chu, K., Palaniappan, K., Ratner, A., Huang, J., Huntemann, M., Hajek,

- 1549 P., Ritter, S., Varghese, N., Seshadri, R., Roux, S., Woyke, T., Eloe-Fadrosh, E. A.,
1550 Ivanova, N. N., & Kyrpides, N. C. (2021). The IMG/M data management and analysis
1551 system v.6.0: new tools and advanced capabilities. *Nucleic Acids Research*, *49*(D1),
1552 D751–D763.
- 1553 15. Chuai, G., Ma, H., Yan, J., Chen, M., Hong, N., Xue, D., Zhou, C., Zhu, C., Chen, K.,
1554 Duan, B., Gu, F., Qu, S., Huang, D., Wei, J., & Liu, Q. (2018). DeepCRISPR: optimized
1555 CRISPR guide RNA design by deep learning. *Genome Biology*, *19*(1), 80.
- 1556 16. Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung,
1557 J., & Zhang, F. (2017). RNA editing with CRISPR-Cas13. *Science*, *358*(6366), 1019–
1558 1027.
- 1559 17. Do, C. B., Woods, D. A., & Batzoglou, S. (2006). CONTRAfold: RNA secondary structure
1560 prediction without physics-based models. *Bioinformatics*, *22*(14), e90–e98.
- 1561 18. Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F.,
1562 Smith, I., Tothova, Z., Wilen, C., Orchard, R., Virgin, H. W., Listgarten, J., & Root, D. E.
1563 (2016). Optimized sgRNA design to maximize activity and minimize off-target effects of
1564 CRISPR-Cas9. *Nature Biotechnology*, *34*(2), 184–191.
- 1565 19. Doench, J. G., Petersen, C. P., & Sharp, P. A. (2003). siRNAs can function as miRNAs.
1566 *Genes & Development*, *17*(4), 438–442.
- 1567 20. East-Seletsky, A., O’Connell, M. R., Knight, S. C., Burstein, D., Cate, J. H. D., Tjian, R.,
1568 & Doudna, J. A. (2016). Two distinct RNase activities of CRISPR-C2c2 enable guide-
1569 RNA processing and RNA detection. *Nature*, *538*(7624), 270–273.
- 1570 21. Forster, S. C., Kumar, N., Anonye, B. O., Almeida, A., Viciani, E., Stares, M. D., Dunn,
1571 M., Mkandawire, T. T., Zhu, A., Shao, Y., Pike, L. J., Louie, T., Browne, H. P., Mitchell,
1572 A. L., Neville, B. A., Finn, R. D., & Lawley, T. D. (2019). A human gut bacterial genome
1573 and culture collection for improved metagenomic analyses. *Nature Biotechnology*, *37*(2),
1574 186–192.
- 1575 22. Guindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., & Gascuel, O.
1576 (2010). New algorithms and methods to estimate maximum-likelihood phylogenies:
1577 assessing the performance of PhyML 3.0. *Systematic Biology*, *59*(3), 307–321.
- 1578 23. Han, S., Zhao, B. S., Myers, S. A., Carr, S. A., He, C., & Ting, A. Y. (2020). RNA-protein
1579 interaction mapping via MS2- or Cas13-based APEX targeting. *Proceedings of the*
1580 *National Academy of Sciences of the United States of America*, *117*(36), 22068–22079.
- 1581 24. Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G.,
1582 Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., Mero, P., Dirks, P., Sidhu, S.,
1583 Roth, F. P., Rissland, O. S., Durocher, D., Angers, S., & Moffat, J. (2015). High-
1584 Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer
1585 Liabilities. *Cell*, *163*(6), 1515–1526.
- 1586 25. *HMMER*. (n.d.). Retrieved February 25, 2022, from <http://hmmer.org>
- 1587 26. Horlbeck, M. A., Gilbert, L. A., Villalta, J. E., Adamson, B., Pak, R. A., Chen, Y., Fields,
1588 A. P., Park, C. Y., Corn, J. E., Kampmann, M., & Weissman, J. S. (2016). Compact and
1589 highly active next-generation libraries for CRISPR-mediated gene repression and
1590 activation. *eLife*, *5*. <https://doi.org/10.7554/eLife.19760>
- 1591 27. Huang, L., Zhang, H., Deng, D., Zhao, K., Liu, K., Hendrix, D. A., & Mathews, D. H.
1592 (2019). LinearFold: linear-time approximate RNA folding by 5'-to-3' dynamic

- 1593 programming and beam search. In *Bioinformatics* (Vol. 35, Issue 14, pp. i295–i304).
1594 <https://doi.org/10.1093/bioinformatics/btz375>
- 1595 28. Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B.,
1596 Cavet, G., & Linsley, P. S. (2003). Expression profiling reveals off-target gene regulation
1597 by RNAi. *Nature Biotechnology*, 21(6), 635–637.
- 1598 29. Kannan, S., Altae-Tran, H., Jin, X., Madigan, V. J., Oshiro, R., Makarova, K. S., Koonin,
1599 E. V., & Zhang, F. (2022). Compact RNA editors with small Cas13 proteins. *Nature*
1600 *Biotechnology*, 40(2), 194–197.
- 1601 30. Karolchik, D., Hinrichs, A. S., Furey, T. S., Roskin, K. M., Sugnet, C. W., Haussler, D., &
1602 Kent, W. J. (2004). The UCSC Table Browser data retrieval tool. *Nucleic Acids*
1603 *Research*, 32(Database issue), D493–D496.
- 1604 31. Katoh, K., Misawa, K., Kuma, K.-I., & Miyata, T. (2002). MAFFT: a novel method for
1605 rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids*
1606 *Research*, 30(14), 3059–3066.
- 1607 32. Kato, K., Zhou, W., Okazaki, S., Isayama, Y., Nishizawa, T., Gootenberg, J. S.,
1608 Abudayyeh, O. O., & Nishimasu, H. (2022). Structure and engineering of the type III-E
1609 CRISPR-Cas7-11 effector complex. *Cell*, 185(13), 2324–2337.e16.
- 1610 33. Kelley, D. R., Snoek, J., & Rinn, J. L. (2016). Basset: learning the regulatory code of the
1611 accessible genome with deep convolutional neural networks. *Genome Research*, 26(7),
1612 990–999.
- 1613 34. Kim, H. K., Kim, Y., Lee, S., Min, S., Bae, J. Y., Choi, J. W., Park, J., Jung, D., Yoon, S.,
1614 & Kim, H. H. (2019). SpCas9 activity prediction by DeepSpCas9, a deep learning-based
1615 model with high generalization performance. In *Science Advances* (Vol. 5, Issue 11, p.
1616 eaax9249). <https://doi.org/10.1126/sciadv.aax9249>
- 1617 35. Kim, H. K., Min, S., Song, M., Jung, S., Choi, J. W., Kim, Y., Lee, S., Yoon, S., & Kim, H.
1618 (henry). (2018). Deep learning improves prediction of CRISPR-Cpf1 guide RNA activity.
1619 *Nature Biotechnology*, 36(3), 239–241.
- 1620 36. Koblan, L. W., Arbab, M., Shen, M. W., Hussmann, J. A., Anzalone, A. V., Doman, J. L.,
1621 Newby, G. A., Yang, D., Mok, B., Replogle, J. M., Xu, A., Sisley, T. A., Weissman, J. S.,
1622 Adamson, B., & Liu, D. R. (2021). Efficient C•G-to-G•C base editors developed using
1623 CRISPRi screens, target-library analysis, and machine learning. *Nature Biotechnology*,
1624 39(11), 1414–1425.
- 1625 37. Konermann, S., Lotfy, P., Brideau, N. J., Oki, J., Shokhirev, M. N., & Hsu, P. D. (2018).
1626 Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. *Cell*,
1627 173(3), 665–676.e14.
- 1628 38. Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z.,
1629 Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., McDermott, M. G., Monteiro,
1630 C. D., Gundersen, G. W., & Ma'ayan, A. (2016). Enrichr: a comprehensive gene set
1631 enrichment analysis web server 2016 update. *Nucleic Acids Research*, 44(W1), W90–
1632 W97.
- 1633 39. Kursu, M. B., Rudnicki, W. R., & Others. (2010). Feature selection with the Boruta
1634 package. *Journal of Statistical Software*, 36(11), 1–13.
- 1635 40. Kushawah, G., Hernandez-Huertas, L., Abugattas-Nuñez Del Prado, J., Martinez-
1636 Morales, J. R., DeVore, M. L., Hassan, H., Moreno-Sanchez, I., Tomas-Gallardo, L.,

- 1637 Diaz-Moscoso, A., Monges, D. E., Guelfo, J. R., Theune, W. C., Brannan, E. O., Wang,
1638 W., Corbin, T. J., Moran, A. M., Sánchez Alvarado, A., Málaga-Trillo, E., Takacs, C.
1639 M., ... Moreno-Mateos, M. A. (2020). CRISPR-Cas13d Induces Efficient mRNA
1640 Knockdown in Animal Embryos. *Developmental Cell*, 54(6), 805–817.e7.
- 1641 41. Lanchantin, J., Singh, R., Lin, Z., & Qi, Y. (2016). Deep Motif: Visualizing Genomic
1642 Sequence Classifications. In *arXiv [cs.LG]*. arXiv. <http://arxiv.org/abs/1605.01133>
- 1643 42. Li, S., Li, X., Xue, W., Zhang, L., Yang, L.-Z., Cao, S.-M., Lei, Y.-N., Liu, C.-X., Guo, S.-
1644 K., Shan, L., Wu, M., Tao, X., Zhang, J.-L., Gao, X., Zhang, J., Wei, J., Li, J., Yang, L., &
1645 Chen, L.-L. (2021). Screening for functional circular RNAs using the CRISPR–Cas13
1646 system. In *Nature Methods* (Vol. 18, Issue 1, pp. 51–59). [https://doi.org/10.1038/s41592-](https://doi.org/10.1038/s41592-020-01011-4)
1647 020-01011-4
- 1648 43. Liu, L., Li, X., Ma, J., Li, Z., You, L., Wang, J., Wang, M., Zhang, X., & Wang, Y. (2017).
1649 The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a. *Cell*, 170(4),
1650 714–726.e10.
- 1651 44. Lorenz, R., Bernhart, S. H., Höner Zu Siederdisen, C., Tafer, H., Flamm, C., Stadler, P.
1652 F., & Hofacker, I. L. (2011). ViennaRNA Package 2.0. *Algorithms for Molecular Biology:*
1653 *AMB*, 6, 26.
- 1654 45. Lundberg, S. M., Erion, G., Chen, H., DeGrave, A., Prutkin, J. M., Nair, B., Katz, R.,
1655 Himmelfarb, J., Bansal, N., & Lee, S.-I. (2020). From Local Explanations to Global
1656 Understanding with Explainable AI for Trees. *Nature Machine Intelligence*, 2(1), 56–67.
- 1657 46. Luo, B., Cheung, H. W., Subramanian, A., Sharifnia, T., Okamoto, M., Yang, X., Hinkle,
1658 G., Boehm, J. S., Beroukhim, R., Weir, B. A., Mermel, C., Barbie, D. A., Awad, T., Zhou,
1659 X., Nguyen, T., Piquani, B., Li, C., Golub, T. R., Meyerson, M., ... Root, D. E. (2008).
1660 Highly parallel identification of essential genes in cancer cells. *Proceedings of the*
1661 *National Academy of Sciences of the United States of America*, 105(51), 20380–20385.
- 1662 47. Mahas, A., Aman, R., & Mahfouz, M. (2019). CRISPR-Cas13d mediates robust RNA
1663 virus interference in plants. *Genome Biology*, 20(1), 263.
- 1664 48. Metsky, H. C., Welch, N. L., Haradhvala, N. J., Rumker, L., Zhang, Y. B., Pillai, P. P.,
1665 Yang, D. K., Ackerman, C. M., Weller, J., Blainey, P. C., Myhrvold, C., Mitzenmacher,
1666 M., & Sabeti, P. C. (2021). Designing viral diagnostics with model-based optimization. In
1667 *bioRxiv* (p. 2020.11.28.401877). <https://doi.org/10.1101/2020.11.28.401877>
- 1668 49. Metsky, H. C., Welch, N. L., Pillai, P. P., Haradhvala, N. J., Rumker, L., Mantena, S.,
1669 Zhang, Y. B., Yang, D. K., Ackerman, C. M., Weller, J., Blainey, P. C., Myhrvold, C.,
1670 Mitzenmacher, M., & Sabeti, P. C. (2022). Designing sensitive viral diagnostics with
1671 machine learning. *Nature Biotechnology*. <https://doi.org/10.1038/s41587-022-01213-5>
- 1672 50. Meyer, F., Paarmann, D., D'Souza, M., Olson, R., Glass, E. M., Kubal, M., Paczian, T.,
1673 Rodriguez, A., Stevens, R., Wilke, A., Wilkening, J., & Edwards, R. A. (2008). The
1674 metagenomics RAST server - a public resource for the automatic phylogenetic and
1675 functional analysis of metagenomes. *BMC Bioinformatics*, 9, 386.
- 1676 51. Mitchell, A. L., Almeida, A., Beracochea, M., Boland, M., Burgin, J., Cochrane, G.,
1677 Crusoe, M. R., Kale, V., Potter, S. C., Richardson, L. J., Sakharova, E., Scheremetjew,
1678 M., Korobeynikov, A., Shlemov, A., Kunyavskaya, O., Lapidus, A., & Finn, R. D. (2020).
1679 MGnify: the microbiome analysis resource in 2020. *Nucleic Acids Research*, 48(D1),
1680 D570–D578.

- 1681 52. Özcan, A., Krajeski, R., Ioannidi, E., Lee, B., Gardner, A., Makarova, K. S., Koonin, E.
1682 V., Abudayyeh, O. O., & Gootenberg, J. S. (2021). Programmable RNA targeting with
1683 the single-protein CRISPR effector Cas7-11. *Nature*, 597(7878), 720–725.
- 1684 53. Pimentel, H., Bray, N. L., Puente, S., Melsted, P., & Pachter, L. (2017). Differential
1685 analysis of RNA-seq incorporating quantification uncertainty. *Nature Methods*, 14(7),
1686 687–690.
- 1687 54. Shi, P., Murphy, M. R., Aparicio, A. O., Kesner, J. S., Fang, Z., Chen, Z., Trehan, A., &
1688 Wu, X. (2021). RNA-guided cell targeting with CRISPR/RfxCas13d collateral activity in
1689 human cells. In *bioRxiv* (p. 2021.11.30.470032).
1690 <https://doi.org/10.1101/2021.11.30.470032>
- 1691 55. Shrikumar, A., Tian, K., Avsec, Ž., Shcherbina, A., Banerjee, A., Sharmin, M., Nair, S., &
1692 Kundaje, A. (2018). Technical Note on Transcription Factor Motif Discovery from
1693 Importance Scores (TF-ModISco) version 0.5.6.5. In *arXiv [cs.LG]*. arXiv.
1694 <http://arxiv.org/abs/1811.00416>
- 1695 56. Sigoillot, F. D., Lyman, S., Huckins, J. F., Adamson, B., Chung, E., Quattrochi, B., &
1696 King, R. W. (2012). A bioinformatics method identifies prominent off-targeted transcripts
1697 in RNAi screens. *Nature Methods*, 9(4), 363–366.
- 1698 57. Slaymaker, I. M., Mesa, P., Kellner, M. J., Kannan, S., Brignole, E., Koob, J., Feliciano,
1699 P. R., Stella, S., Abudayyeh, O. O., Gootenberg, J. S., Strecker, J., Montoya, G., &
1700 Zhang, F. (2021). High-resolution structure of cas13b and biochemical characterization
1701 of RNA targeting and cleavage. In *Cell Reports* (Vol. 34, Issue 10, p. 108865).
1702 <https://doi.org/10.1016/j.celrep.2021.108865>
- 1703 58. Steinegger, M., & Söding, J. (2017). MMseqs2 enables sensitive protein sequence
1704 searching for the analysis of massive data sets. *Nature Biotechnology*, 35(11), 1026–
1705 1028.
- 1706 59. Sunagawa, S., Coelho, L. P., Chaffron, S., Kultima, J. R., Labadie, K., Salazar, G.,
1707 Djahanschiri, B., Zeller, G., Mende, D. R., Alberti, A., Cornejo-Castillo, F. M., Costea, P.
1708 I., Cruaud, C., d'Ovidio, F., Engelen, S., Ferrera, I., Gasol, J. M., Guidi, L., Hildebrand,
1709 F., ... Bork, P. (2015). Ocean plankton. Structure and function of the global ocean
1710 microbiome. *Science*, 348(6237), 1261359.
- 1711 60. Sundararajan, M., Taly, A., & Yan, Q. (2017). Axiomatic Attribution for Deep Networks.
1712 In D. Precup & Y. W. Teh (Eds.), *Proceedings of the 34th International Conference on*
1713 *Machine Learning* (Vol. 70, pp. 3319–3328). PMLR.
- 1714 61. Wayment-Steele, H. K., Kladwang, W., Participants, E., & Das, R. (2020). RNA
1715 secondary structure packages ranked and improved by high-throughput experiments. In
1716 *bioRxiv* (p. 2020.05.29.124511). <https://doi.org/10.1101/2020.05.29.124511>
- 1717 62. Wessels, H.-H., Méndez-Mancilla, A., Guo, X., Legut, M., Daniloski, Z., & Sanjana, N. E.
1718 (2020). Massively parallel Cas13 screens reveal principles for guide RNA design. *Nature*
1719 *Biotechnology*, 38(6), 722–727.
- 1720 63. Wilson, C., Chen, P. J., Miao, Z., & Liu, D. R. (2020). Programmable m6A modification of
1721 cellular RNAs with a Cas13-directed methyltransferase. In *Nature Biotechnology* (Vol.
1722 38, Issue 12, pp. 1431–1440). <https://doi.org/10.1038/s41587-020-0572-6>
- 1723 64. Xie, Z., Bailey, A., Kuleshov, M. V., Clarke, D. J. B., Evangelista, J. E., Jenkins, S. L.,
1724 Lachmann, A., Wojciechowicz, M. L., Kropiwnicki, E., Jagodnik, K. M., Jeon, M., &

- 1725 Ma'ayan, A. (2021). Gene Set Knowledge Discovery with Enrichr. *Current Protocols*,
1726 1(3), e90.
- 1727 65. Xu, C., Zhou, Y., Xiao, Q., He, B., Geng, G., Wang, Z., Cao, B., Dong, X., Bai, W.,
1728 Wang, Y., Wang, X., Zhou, D., Yuan, T., Huo, X., Lai, J., & Yang, H. (2021).
1729 Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated
1730 microbes. *Nature Methods*, 18(5), 499–506.
- 1731 66. Xue, L., Tang, B., Chen, W., & Luo, J. (2019). Prediction of CRISPR sgRNA Activity
1732 Using a Deep Convolutional Neural Network. *Journal of Chemical Information and*
1733 *Modeling*, 59(1), 615–624.
- 1734 67. Youngblut, N. D., de la Cuesta-Zuluaga, J., Reischer, G. H., Dauser, S., Schuster, N.,
1735 Walzer, C., Stalder, G., Farnleitner, A. H., & Ley, R. E. (2020). Large-Scale Metagenome
1736 Assembly Reveals Novel Animal-Associated Microbial Genomes, Biosynthetic Gene
1737 Clusters, and Other Genetic Diversity. *mSystems*, 5(6).
1738 <https://doi.org/10.1128/mSystems.01045-20>
- 1739 68. Yu, G. (2020). Using ggtree to Visualize Data on Tree-Like Structures. *Current Protocols*
1740 *in Bioinformatics / Editorial Board, Andreas D. Baxevanis ... [et Al.]*, 69(1), e96.
- 1741 69. Zhang, C., Konermann, S., Brideau, N. J., Lotfy, P., Wu, X., Novick, S. J., Strutzenberg,
1742 T., Griffin, P. R., Hsu, P. D., & Lyumkis, D. (2018). Structural Basis for the RNA-Guided
1743 Ribonuclease Activity of CRISPR-Cas13d. *Cell*, 175(1), 212–223.e17.